3.4.21.98	((1R,2S)-1-((2S,4S)-1-((S)-2-(((cyclopentyloxy)carbonyl)amino)-3,3-dimethylbutanoyl)-4-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)pyrrolidine-2-carboxamido)-2-vinylcyclopropyl)(ethyl)phosphinic acid	-	86152	
3.4.21.98	((1R,2S)-1-((2S,4S)-1-((S)-2-(((cyclopentyloxy)carbonyl)amino)-3,3-dimethylbutanoyl)-4-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)pyrrolidine-2-carboxamido)-2-vinylcyclopropyl)(methyl)phosphinic acid	-	86151	
3.4.21.98	(+)-usnic acid	90.7% inhibition, the most active compound and could be used as a lead compound in developing novel anti-HCV agents. The major amino acid residues of NS3 protease likely involved in the interaction with (+)-usnic acid are Gln41, Ser42, Phe43, His57, Arg10	235331	
3.4.21.98	(-)-epicatechin-3-O-gallate	-	7630	
3.4.21.98	(-)-epigallocatechin-3-O-gallate	-	1889	
3.4.21.98	(1'R,21'S,24'S)-21'-tert-butyl-N-((1R,2R)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-ethylcyclopropyl)-3',19',22'-trioxo-2',18'-dioxa-4',20',23'-triazaspiro[cyclobutane-1,16'-tetracyclo-[21.2.1.14,7.06,11]heptacosane]-6',8',10'-triene-24'-carboxamide	-	81032	
3.4.21.98	(1'R,21'S,24'S)-21'-tert-butyl-N-((1R,2R)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-ethylcyclopropyl)-3',19',22'-trioxo-2',18'-dioxa-4',20',23'-triazaspiro[cyclohexane-1,16'-tetracyclo-[21.2.1.14,7.06,11]heptacosane]-6',8',10'-triene-24'-carboxamide	-	81034	
3.4.21.98	(1'R,21'S,24'S)-21'-tert-butyl-N-((1R,2R)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-ethylcyclopropyl)-3',19',22'-trioxo-2',18'-dioxa-4',20',23'-triazaspiro[cyclopentane-1,16'-tetracyclo-[21.2.1.14,7.06,11]heptacosane]-6',8',10'-triene-24'-carboxamide	-	81033	
3.4.21.98	(1'R,21'S,24'S)-21'-tert-butyl-N-((1R,2R)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-ethylcyclopropyl)-3',19',22'-trioxo-2',18'-dioxa-4',20',23'-triazaspiro[cyclopropane-1,16'-tetracyclo-[21.2.1.14,7.06,11]heptacosane]-6',8',10'-triene-24'-carboxamide	-	81031	
3.4.21.98	(10R,13R)-N-(1-[[(2-[[(1R)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-10-cyclohexyl-8,11-dioxo-2-oxa-9,12-diazabicyclo[13.3.1]nonadeca-1(19),15,17-triene-13-carboxamide	-	68578	
3.4.21.98	(10S,13S)-10-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-11-oxo-2,7-dioxa-8-thia-9,12-diazabicyclo[13.3.1]nonadeca-1(19),15,17-triene-13-carboxamide 8,8-dioxide	-	68579	
3.4.21.98	(10S,13S)-10-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-8,11-dioxo-2,7-dioxa-9,12-diazabicyclo[13.3.1]nonadeca-1(19),15,17-triene-13-carboxamide	-	68580	
3.4.21.98	(10S,13S)-10-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-8,11-dioxo-2-oxa-9,12-diazabicyclo[13.3.1]nonadeca-1(19),15,17-triene-13-carboxamide	-	68588	
3.4.21.98	(10S,13S)-10-cyclohexyl-N-(1-[[(2-[[(1S)-2-(methylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-8,11-dioxo-2-oxa-9,12-diazabicyclo[13.3.1]nonadeca-1(19),15,17-triene-13-carboxamide	-	68589	
3.4.21.98	(11R,14R)-N-(1-[[(2-[[(1R)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-11-cyclohexyl-9,12-dioxo-2-oxa-10,13-diazabicyclo[14.3.1]icosa-1(20),16,18-triene-14-carboxamide	-	68590	
3.4.21.98	(11S,14S)-N-(1-[[(2-[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-11-cyclohexyl-9,12-dioxo-1,10,13,17-tetraazabicyclo[14.2.1]nonadeca-16(19),17-diene-14-carboxamide	-	68591	
3.4.21.98	(11Z,13aR,15aS)-N-(cyclopropylsulfonyl)-2-([7-methoxy-8-methyl-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinolin-4-yl]oxy)-15-oxo-1,2,3,7,8,9,10,12a,13,14,15,15a-dodecahydrocyclopropa[f]pyrrolo[1,2-b][1,2,5]thiadiazacyclotetradecine-13a(6H)-carboxamide 5,5-dioxide	most potent inhibitor of the series with sulfonamide linkage. The microsomally predicted clearance numbers is 0.17/0.7 L/h/kg (h/r)	199420	
3.4.21.98	(11Z,13aR,15aS)-N-(cyclopropylsulfonyl)-2-([7-methoxy-8-methyl-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinolin-4-yl]oxy)-5,15-dioxo-1,2,3,5,6,7,8,9,10,12a,13,14,15,15a-tetradecahydro-13aH-cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotetradecine-13a-carboxamide	inhibitor with proline amide linkage, slightly more potent than inhibitors with sulfonamide linkage. The microsomally predicted clearance number is 0.17/0.82 L/h/kg (h/r)	199421	
3.4.21.98	(1aR,5S,10R,22aR)-5-tert-butyl-9-cyclopropyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl]-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide	-	235337	
3.4.21.98	(1aR,5S,10R,22aR)-5-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl]-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide	-	235338	
3.4.21.98	(1aR,5S,10R,22aR)-5-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl]-14-methoxy-3,6-dioxo-9-propyl-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide	-	235339	
3.4.21.98	(1aR,5S,10R,22aR)-5-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl]-14-methoxy-9-methyl-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide	-	235340	
3.4.21.98	(1aR,5S,10R,22aR)-5-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl]-9-ethyl-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide	-	235341	
3.4.21.98	(1aR,5S,10R,22aR)-9-(butan-2-yl)-5-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl]-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide	-	235342	
3.4.21.98	(1aR,5S,10S,22aR)-5-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl]-14-methoxy-3,6-dioxo-9-phenoxy-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide	-	235343	
3.4.21.98	(1aR,5S,8S,9S,10R,19E,22aR)-5-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl]-9-ethyl-18,18-difluoro-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,21,22,22a-dodecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide	-	235344	
3.4.21.98	(1aR,5S,8S,9S,10R,21aR)-5-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl]-9-ethyl-14-methoxy-3,6-dioxo-1a,3,4,5,6,9,10,17b,18,18a,19,20,21,21a-tetradecahydro-1H,8H-7,10-methanodicyclopropa[13,14:18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide	-	235345	
3.4.21.98	(1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-[(1R,2R)-1-[(cyclopropanesulfonyl)carbamoyl]-2-(difluoromethyl)cyclopropyl]-9-ethyl-18,18-difluoro-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide	-	235346	
3.4.21.98	(1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-[(1R,2R)-1-[(cyclopropanesulfonyl)carbamoyl]-2-ethylcyclopropyl]-18,18-difluoro-14-methoxy-9-methyl-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide	-	235347	
3.4.21.98	(1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-[(1R,2R)-1-[(cyclopropanesulfonyl)carbamoyl]-2-ethylcyclopropyl]-9-ethyl-18,18-difluoro-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide	-	235348	
3.4.21.98	(1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-[(1R,2R)-1-[(cyclopropanesulfonyl)carbamoyl]-2-methylcyclopropyl]-9-ethyl-18,18-difluoro-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide	-	235349	
3.4.21.98	(1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl]-9-ethyl-18,18-difluoro-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide	-	235350	
3.4.21.98	(1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl]-9-ethyl-18-fluoro-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide	-	235351	
3.4.21.98	(1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-[(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]-2-(2,2-difluoroethyl)cyclopropyl]-18,18-difluoro-14-methoxy-9-methyl-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide	-	235352	
3.4.21.98	(1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-[(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]-2-(2-fluoroethyl)cyclopropyl]-18,18-difluoro-14-methoxy-9-methyl-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide	-	235353	
3.4.21.98	(1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-[(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]-2-ethenylcyclopropyl]-18,18-difluoro-14-methoxy-9-methyl-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide	-	235354	
3.4.21.98	(1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-[(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]-2-ethenylcyclopropyl]-9-ethyl-18,18-difluoro-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide	-	235355	
3.4.21.98	(1R)-1-([(4R)-1-[(2S)-2-[(tert-butoxycarbonyl)amino]heptanoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolyl]amino)-2-ethenylcyclopropanecarboxylic acid	50% inhibition at 0.0000004 mM, NMR and molecular dynamics analysis	35715	
3.4.21.98	(1R)-1-([(4R)-1-[(2S)-2-[(tert-butoxycarbonyl)amino]heptanoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolyl]amino)-2-ethenylcyclopropanecarboxylic acid	-	35715	
3.4.21.98	(1R)-2-but-3-en-1-yl-1-[[(4R)-1-[(2S)-2-[(tert-butoxycarbonyl)amino]hept-6-enoyl]-4-(quinolin-4-yloxy)-L-prolyl]amino]cyclopropanecarboxylic acid	-	68593	
3.4.21.98	(1R,12E,19S,22S)-19-tert-butyl-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-vinylcyclopropyl)-3,17,20-trioxo-2,16-dioxa-4,18,21-triazatetracyclo[19.2.1.14,7.06,11]pentacosa-6,8,10,12-tetraene-22-carboxamide	-	81024	
3.4.21.98	(1R,12E,20S,23S)-20-butyl-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-vinylcyclopropyl)-3,18,21-trioxo-2,17-dioxa-4,19,22-triazatetracyclo[20.2.1.14,7.06,11]hexacosa-6,8,10,12-tetraene-23-carboxamide	-	81019	
3.4.21.98	(1R,12E,20S,23S)-20-cyclohexyl-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-vinylcyclopropyl)-3,18,21-trioxo-2,17-dioxa-4,19,22-triazatetracyclo[20.2.1.14,7.06,11]hexacosa-6,8,10,12-tetraene-23-carboxamide	-	81021	
3.4.21.98	(1R,12E,20S,23S)-20-cyclopentyl-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-vinylcyclopropyl)-3,18,21-trioxo-2,17-dioxa-4,19,22-triazatetracyclo[20.2.1.14,7.06,11]hexacosa-6,8,10,12-tetraene-23-carboxamide	-	81023	
3.4.21.98	(1R,12E,20S,23S)-20-tert-butyl-N-((1R,2R)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-ethylcyclopropyl)-3,18,21-trioxo-2,17-dioxa-4,19,22-triazatetracyclo[20.2.1.14,7.06,11]hexacosa-6,8,10,12-tetraene-23-carboxamide	-	81028	
3.4.21.98	(1R,12E,20S,23S)-20-tert-butyl-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-vinylcyclopropyl)-3,18,21-trioxo-2,17-dioxa-4,19,22-triazatetracyclo[20.2.1.14,7.06,11]hexacosa-6,8,10,12-tetraene-23-carboxamide	-	81018	
3.4.21.98	(1R,12E,20S,23S)-20-tert-butyl-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-vinylcyclopropyl)-4-methyl-3,18,21-trioxo-2,17-dioxa-4,19,22-triazatricyclo[20.2.1.06,11]pentacosa-6,8,10,12-tetraene-23-carboxamide	-	81014	
3.4.21.98	(1R,12E,20S,23S)-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]-carbonyl]-2-vinylcyclopropyl)-20-(1-methylcyclohexyl)-3,18,21-trioxo-2,17-dioxa-4,19,22-triazatetracyclo[20.2.1.14,7.06,11]hexacosa-6,8,10,12-tetraene-23-carboxamide	-	81022	
3.4.21.98	(1R,12E,20S,23S)-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]-carbonyl]-2-vinylcyclopropyl)-20-isopropyl-3,18,21-trioxo-2,17-dioxa-4,19,22-triazatetracyclo[20.2.1.14,7.06,11]hexacosa-6,8,10,12-tetraene-23-carboxamide	-	81020	
3.4.21.98	(1R,12E,21S,24S)-21-tert-butyl-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-vinylcyclopropyl)-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,7.06,11]heptacosa-6,8,10,12-tetraene-24-carboxamide	-	81025	
3.4.21.98	(1R,12E,22S,25S)-22-tert-butyl-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-vinylcyclopropyl)-3,20,23-trioxo-2,19-dioxa-4,21,24-triazatetracyclo[22.2.1.14,7.06,11]octacosa-6,8,10,12-tetraene-25-carboxamide	-	81026	
3.4.21.98	(1R,20S,23S)-20-tert-butyl-N-((1R,2R)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-ethylcyclopropyl)-3,18,21-trioxo-2,17-dioxa-4,19,22-triazatetracyclo[20.2.1.14,7.06,11]hexacosa-6,8,10-triene-23-carboxamide	-	81029	
3.4.21.98	(1R,20S,23S)-20-tert-butyl-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-vinylcyclopropyl)-3,18,21-trioxo-2,17-dioxa-4,19,22-triazatetracyclo[20.2.1.14,7.06,11]hexacosa-6,8,10-triene-23-carboxamide	-	81027	
3.4.21.98	(1R,21S,24S)-21-(tert-butoxymethyl)-N-((1R,2R)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-ethylcyclopropyl)-16,16-dimethyl-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,7.06,11]-heptacosa-6,8,10-triene-24-carboxamide	-	81037	
3.4.21.98	(1R,21S,24S)-21-cyclohexyl-N-((1R,2R)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-ethylcyclopropyl)-16,16-dimethyl-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,7.06,11]-heptacosa-6,8,10-triene-24-carboxamide	-	81035	
3.4.21.98	(1R,21S,24S)-21-tert-butyl-N-((1R,2R)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-ethylcyclopropyl)-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,7.06,11]heptacosa-6,8,10-triene-24-carboxamide	-	81030	
3.4.21.98	(1R,21S,24S)-N-((1R,2R)-1-[[(cyclopropylsulfonyl)amino]-carbonyl]-2-ethylcyclopropyl)-16,16-dimethyl-21-(1-methylcyclohexyl)-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,7.06,11]heptacosa-6,8,10-triene-24-carboxamide	-	81036	
3.4.21.98	(1R,2S)-1-[([(1R,2R,4S)-2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]-2,2-dimethylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopentyl]carbonyl)amino]-2-ethenylcyclopropanecarboxylic acid	-	68594	
3.4.21.98	(1R,2S)-1-[([(1R,4R)-2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]-2,2-dimethylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl]carbonyl)amino]-2-ethenylcyclopropanecarboxylic acid	-	68595	
3.4.21.98	(1R,2S)-1-[([(1R,4R)-2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-methoxy-2-oxoethyl]carbamoyl]-2,2-dimethylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl]carbonyl)amino]-2-ethenylcyclopropanecarboxylic acid	-	68560	
3.4.21.98	(1R,2S)-1-[([(1S,4S)-2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]-2,2-dimethylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl]carbonyl)amino]-2-ethenylcyclopropanecarboxylic acid	-	68585	
3.4.21.98	(1R,2S)-1-[([(1S,4S)-2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-methoxy-2-oxoethyl]carbamoyl]-2,2-dimethylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl]carbonyl)amino]-2-ethenylcyclopropanecarboxylic acid	-	68583	
3.4.21.98	(1R,2S)-1-[[(1R,2R,4S)-2-((S)-1-cyclopentylcarbamoyl-2,2-dimethyl-propylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid	-	71634	
3.4.21.98	(1R,2S)-1-[[(1R,2R,4S)-2-((S)-1-tert-butylcarbamoyl-2,2-dimethyl-propylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid	-	71635	
3.4.21.98	(1R,2S)-1-[[(1R,2R,4S)-2-[(S)-1-[((S)-cyclohexyldimethylcarbamoyl-methyl)-carbamoyl]-2,2-dimethylpropylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid	-	71632	
3.4.21.98	(1R,2S)-1-[[(1R,2R,4S)-2-[(S)-1-[((S)-cyclohexylmethylcarbamoyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid	-	71631	
3.4.21.98	(1R,2S)-1-[[(1R,2R,4S)-2-[(S)-1-[((S)-cyclohexylmethylcarbamoyl-methyl)-methyl-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid	-	71633	
3.4.21.98	(1R,2S)-1-[[(2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl](methyl)carbamoyl]-2,2-dimethylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl)carbonyl]amino]-2-ethenylcyclopropanecarboxylic acid	-	68550	
3.4.21.98	(1R,2S)-1-[[(2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-methoxy-2-oxoethyl]carbamoyl]-2-methylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl)carbonyl]amino]-2-ethenylcyclopropanecarboxylic acid	-	68551	
3.4.21.98	(1R,5S)-3-(N-[[(1S)-1-cyclohexyl-2-cyclopropyl-2-oxoethyl]carbamoyl]-3-methyl-L-valyl)-N-[1-(cyclopropylamino)-1,2-dioxohept-6-yn-3-yl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide	-	86417	
3.4.21.98	(1R,5S)-3-[2(S)-[[[[1-[(1-azetidinylsulfonyl)methyl]-cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]butyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide	-	167611	
3.4.21.98	(1R,5S)-3-[2(S)-[[[[1-[[[cyclobutyl(methyl)amino]sulfonyl]methyl]cyclohexyl]amino] carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]-butyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide	-	86200	
3.4.21.98	(1R,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[N-(tert-butylcarbamoyl)-3-methyl-L-valyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide	-	86415	
3.4.21.98	(1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyll]-butyl]-3-[2(S)-[[[[1-[[(dimethylamino)sulfonyl]methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide	-	86196	
3.4.21.98	(1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]-butyl]-3-[(2S)-2-[[[[1-[1(R)-[(dimethylamino)sulfonyl]ethyl]-cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyll-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide	-	86203	
3.4.21.98	(1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]-butyl]-3-[(2S)-[[[[1-[1(S)-[(dimethylamino)sulfonyl]ethyl]-cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyll-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide	-	167612	
3.4.21.98	(1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]-butyl]-3-[2(S)-[[[[1-(2-cyclopropyl-1,1-dioxido-5(R)-isothiazolidinyl)cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide	-	86205	
3.4.21.98	(1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]-butyl]-3-[2(S)-[[[[1-[[[(2-fluoro-1,1-dimethylethyl)methylamino]sulfonyl]methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]-hexane-2(S)-carboxamide	-	86198	
3.4.21.98	(1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]-butyl]-3-[2(S)-[[[[1-[[[(cyclopropylmethyl)methylamino]sulfonyl]methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide	-	167610	
3.4.21.98	(1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]-butyl]-3-[2(S)-[[[[1-[[[cyclopropyl(1-methylethyl)amino]-sulfonyl]methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide	-	86201	
3.4.21.98	(1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]-butyl]-3-[2(S)-[[[[1-[[[cyclopropyl(methyl)amino]sulfonyl]-methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide	-	86199	
3.4.21.98	(1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]-butyl]-3-[2(S)-[[[[1-[[[ethyl(methyl)amino]sulfonyl]methyl]-cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide	-	86418	
3.4.21.98	(1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]-butyl]-3-[3,3-dimethyl-2(S)-[[[[1-[(4-morpholinylsulfonyl)-methyl]cyclohexyl]amino]carbonyl]amino]-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide	-	86202	
3.4.21.98	(1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]-butyl]-3-[3,3-dimethyl-2(S)-[[[[1-[[(methylamino)sulfonyl]-methyl]cyclohexyl]amino]carbonyl]amino]-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide	-	167609	
3.4.21.98	(1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]-butyl]-3-[3,3-dimethyl-2(S)-[[[[1-[[[methyl(1-me5thylethyl)-amino]sulfonyl]methyl]cyclohexyl]amino]carbonyl]amino]-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide	-	86197	
3.4.21.98	(1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]-pemtyl]-3-[2(S)-[[[[1-[[[cyclopropyl(methyl)amino]sulfonyl]-methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide	-	86207	
3.4.21.98	(1R,5S)-N-[3-(cyclopropylamino)-1(S)-(2-cyclopropylethyl)-2,3-dioxopropyl]-3-[2(S)-[[[[1-[[[cycloppropyl(methyl)-amino]sulfonyl]methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]-hexane-2(S)-carboxamide	-	86204	
3.4.21.98	(1R,5S)-N-[3-(cyclopropylamino)-1(S)-(cyclopropylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[[1-[[[cyclopropyl(methyl)-amino]sulfonyl]methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]-hexane-2(S)-carboxamide	-	86206	
3.4.21.98	(1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide	Boceprevir: EC50 and EC90 values, determined in a bicistronic, subgenomic, cell-based replicon assay run over 72 h using Huh-7 hepatoma cells, are 200 and 400 nM, respectively. Preclinical, metabolism and pharmacokinetics data are very promising. Currently ongoing phase II clinical trials demonstrate the compound to be well tolerated	75369	
3.4.21.98	(1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide	-	72488	
3.4.21.98	(1S,5R)-6,6-dichloro-3-[cyclohexyl[[[(1,1-dimethylethyl)amino]carbonyl]amino]acetyl]-N-[1-[1,2-dioxo-2-(2-propenylamino)ethyl]butyl]-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide	-	25498	
3.4.21.98	(1S,5R)-N-((S)-5-cyclopropyl-1-(cyclopropylamino)-1,2-dioxopentan-3-yl)-3-((S)-2-(3-(1-((N-cyclopropyl-N-methylsulfamoyl)methyl)cyclohexyl)ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide	-	86208	
3.4.21.98	(1S,5R)-N-(1-amino-5,5-difluoro-1,2-dioxoheptan-3-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide	-	72555	
3.4.21.98	(1S,5R)-N-(1-amino-5,5-difluoro-1,2-dioxohexan-3-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide	-	72556	
3.4.21.98	(1S,5R)-N-(1-amino-6,6,6-trifluoro-1,2-dioxohexan-3-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide	-	72557	
3.4.21.98	(1S,5R)-N-(1-amino-7,7,7-trifluoro-1,2-dioxoheptan-3-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide	-	72558	
3.4.21.98	(1S,5R)-N-(4-amino-1-((1s,3S)-3-hydroxycyclobutyl)-3,4-dioxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide	-	72559	
3.4.21.98	(1S,5R)-N-(4-amino-1-(1-fluorocyclobutyl)-3,4-dioxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide	-	72560	
3.4.21.98	(1S,5R)-N-(4-amino-1-(1-hydroxycyclobutyl)-3,4-dioxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide	-	72561	
3.4.21.98	(1S,5R)-N-(4-amino-1-(2,2-difluorocyclopropyl)-3,4-dioxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide	-	72562	
3.4.21.98	(1S,5R)-N-(4-amino-1-(3,3-difluorocyclobutyl)-3,4-dioxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide	-	72563	
3.4.21.98	(1S,5R)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide	-	26060	
3.4.21.98	(1S,5R)-N-(5-amino-1,1,1-trifluoro-4,5-dioxopentan-3-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide	-	72564	
3.4.21.98	(2-(3-((12-cyclohexyl-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo-(14.3.1.17,10)henicosa-1(19),16(20),17-triene-9-carbonyl)amino)-2-oxohexanoylamino)acetylamino)phenylacetic acid	-	59696	
3.4.21.98	(2-(3-((12-cyclohexyl-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo-(14.3.1.17,10)henicosa-1(19),16(20),17-triene-9-carbonyl)amino)-2-oxohexanoylamino)acetylamino)phenylacetic acid tert-butyl ester	-	59695	
3.4.21.98	(2-(3-((12-cyclohexyl-5,5-dimethyl-11,14-dioxo-2,6-dioxa-10,-13-diazatricyclo(14.3.1.17,10)henicosa-1(19),16(20),17-triene-9-carbonyl)amino)-2-oxohexanoylamino)acetylamino)phenylacetic acid tert-butyl ester	-	59701	
3.4.21.98	(2-(3-((3-cyclohexyl-2,5-dioxo-12-oxa-1,4-diazatricyclo(11.5.3.016,20)henicosa-13(21),14,16(20)-triene-18-carbonyl)amino)-2-oxohexanoylamino)acetylamino)phenylacetic acid	-	59694	
3.4.21.98	(2-(3-((3-cyclohexyl-2,5-dioxo-12-oxa-1,4-diazatricyclo(11.5.3.016,20)henicosa-13(21),14,16(20)-triene-18-carbonyl)amino)-2-oxohexanoylamino)acetylamino)phenylacetic acid tert-butyl ester	-	59693	
3.4.21.98	(2R)-([N-[3-([[(9S,12S)-12-cyclohexyl-11,14-dioxo-2,10-dioxa-13-azatricyclo[15.2.2.13,7]docosa-1(19),3(22),4,6,17,20-hexaen-9-yl]carbonyl]amino)-2-oxohexanoyl]glycyl]amino)(phenyl)ethanoic acid	-	68554	
3.4.21.98	(2R)-([N-[3-([[(9S,12S)-12-cyclohexyl-11,14-dioxo-2-oxa-10,13-diazatricyclo[15.2.2.13,7]docosa-1(19),3(22),4,6,17,20-hexaen-9-yl]carbonyl]amino)-2-oxohexanoyl]glycyl]amino)(phenyl)ethanoic acid	-	68555	
3.4.21.98	(2R)-([N-[3-([[(9S,12S)-12-cyclohexyl-11,14-dioxo-2-oxa-10,13-diazatricyclo[16.2.2.13,7]tricosa-1(20),3(23),4,6,18,21-hexaen-9-yl]carbonyl]amino)-2-oxohexanoyl]glycyl]amino)(phenyl)ethanoic acid	-	68556	
3.4.21.98	(2R)-2-(acetylamino)-3-(4-hydroxy-3,5-diiodophenyl)propanoic acid	-	53380	
3.4.21.98	(2R)-2-[(tert-butoxycarbonyl)amino]-3-(4-hydroxy-3,5-diiodophenyl)propanoic acid	-	53381	
3.4.21.98	(2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-[(7-methoxy-2-phenylquinazolin-4-yl)oxy]-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide	-	86163	
3.4.21.98	(2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-[(7-methoxy-8-methyl-2-phenylquinazolin-4-yl)oxy]-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide	-	41785	
3.4.21.98	(2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-[(7-methoxy-8-methylquinazolin-4-yl)oxy]-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide	-	167602	
3.4.21.98	(2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-[[2-(4-fluorophenyl)-7-methoxy-8-methylquinazolin-4-yl]oxy]-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide	-	86427	
3.4.21.98	(2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-[[7-methoxy-2-(4-methoxyphenyl)-8-methylquinazolin-4-yl]oxy]-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide	-	86165	
3.4.21.98	(2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-[[7-methoxy-8-methyl-2-(6-methylpyridin-2-yl)quinazolin-4-yl]oxy]-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide	-	86166	
3.4.21.98	(2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-[[7-methoxy-8-methyl-2-(pyridin-3-yl)quinazolin-4-yl]oxy]-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide	-	86167	
3.4.21.98	(2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-[[7-methoxy-8-methyl-2-(pyridin-4-yl)quinazolin-4-yl]oxy]-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide	-	86168	
3.4.21.98	(2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-5-methyl-2-[[2-(morpholin-4-yl)quinazolin-4-yl]oxy]-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide	-	86160	
3.4.21.98	(2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-5-methyl-4,14-dioxo-2-[(2-phenylquinazolin-4-yl)oxy]-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide	-	86159	
3.4.21.98	(2R,4S,7S,14Z)-7-tert-butyl-N-[(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl]-6,9-dioxo-3,4,6,7,8,9,12,13-octahydro-2H,11H-16,18-etheno-2,5-methanopyrido[2,3-k][1,10,3,6]dioxadiazacyclononadecine-4-carboxamide	-	159986	
3.4.21.98	(2R,6R,12Z,13aR,14S,16aS)-6-[[(cyclopentyloxy)carbonyl]amino]-2-([7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14-carboxylic acid	-	86419	
3.4.21.98	(2R,6S,10E,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-5,16-dioxo-1,2,3,6,7,8,9,12,13,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid	50% inhibition at 0.000077 mM, NMR and molecular dynamics analysis	35712	
3.4.21.98	(2R,6S,10E,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-5,16-dioxo-1,2,3,6,7,8,9,12,13,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid	-	35712	
3.4.21.98	(2R,6S,10E,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-5,16-dioxo-2-(quinolin-4-yloxy)-1,2,3,6,7,8,9,12,13,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid	-	68557	
3.4.21.98	(2R,6S,10Z,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-5,16-dioxo-1,2,3,6,7,8,9,12,13,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid	-	68558	
3.4.21.98	(2R,6S,12Z,13aS,14aR,16aS)-6-[[(cyclopentyloxy)carbonyl]amino]-2-([7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy)-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine	-	40273	
3.4.21.98	(2R,6S,12Z,14aR,16aS)-2-[(8-chloro-2-ethoxyquinolin-4-yl)oxy]-6-[[(cyclopentyloxy)carbonyl]amino]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid	-	68572	
3.4.21.98	(2R,6S,12Z,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-([7-methoxy-2-[2-(methylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy)-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid	-	68161	
3.4.21.98	(2R,6S,12Z,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid	50% inhibition at 0.000011 mM, NMR and molecular dynamics analysis	35714	
3.4.21.98	(2R,6S,12Z,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid	-	35714	
3.4.21.98	(2R,6S,12Z,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-[(7-methoxyquinolin-4-yl)oxy]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid	-	68559	
3.4.21.98	(2R,6S,12Z,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-[[(4-fluoro-1,3-dihydro-2H-isoindol-2-yl)carbonyl]oxy]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid	-	68549	
3.4.21.98	(2R,6S,12Z,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-[[2-(1H-imidazol-1-yl)-7-methoxyquinolin-4-yl]oxy]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid	-	68561	
3.4.21.98	(2R,6S,12Z,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-[[7-methoxy-2-(1H-pyrazol-1-yl)quinolin-4-yl]oxy]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid	-	68562	
3.4.21.98	(2R,6S,12Z,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-[[7-methoxy-2-(1H-pyrrol-1-yl)quinolin-4-yl]oxy]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid	-	68563	
3.4.21.98	(2R,6S,12Z,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-[[7-methoxy-2-(4-methyl-1H-pyrazol-1-yl)quinolin-4-yl]oxy]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid	-	68564	
3.4.21.98	(2R,6S,12Z,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-[[7-methoxy-2-(5-methyl-1,3,4-oxadiazol-2-yl)quinolin-4-yl]oxy]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid	-	68162	
3.4.21.98	(2R,6S,12Z,14aR,16aS)-6-[[(cyclopentyloxy)carbonyl]amino]-2-[(5-ethoxythieno[3,2-b]pyridin-7-yl)oxy]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid	-	68565	
3.4.21.98	(2R,6S,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-5,16-dioxohexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid	50% inhibition at 0.000027 mM, NMR and molecular dynamics analysis	35713	
3.4.21.98	(2R,6S,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-5,16-dioxohexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid	-	35713	
3.4.21.98	(2S)-([N-[3-([[(10S,13S)-10-cyclohexyl-8,11-dioxo-2,7-dioxa-9,12-diazabicyclo[13.3.1]nonadeca-1(19),15,17-trien-13-yl]carbonyl]amino)-2-oxohexanoyl]glycyl]amino)(phenyl)ethanoic acid	-	68566	
3.4.21.98	(2S)-([N-[3-([[(3S,18S)-18-cyclohexyl-16,19-dioxo-3,4-dihydro-1H-7,2-(epoxyheptanoiminoethano)isoquinolin-3-yl]carbonyl]amino)-2-oxohexanoyl]glycyl]amino)(phenyl)ethanoic acid	-	68567	
3.4.21.98	(2S)-([N-[3-([[(3S,6S)-6-cyclohexyl-5,8-dioxo-4,7-diazabicyclo[14.3.1]icosa-1(20),16,18-trien-3-yl]carbonyl]amino)-2-oxohexanoyl]glycyl]amino)(phenyl)ethanoic acid	-	68568	
3.4.21.98	(2S)-([N-[3-([[(7R,9S,12S)-12-cyclohexyl-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-trien-9-yl]carbonyl]amino)-2-oxohexanoyl]glycyl]amino)(phenyl)ethanoic acid	-	68569	
3.4.21.98	(2S)-([N-[3-([[(9S,12S)-12-cyclohexyl-11,14-dioxo-2-oxa-10,13-diazatricyclo[17.2.2.13,7]tetracosa-1(21),3(24),4,6,19,22-hexaen-9-yl]carbonyl]amino)-2-oxohexanoyl]glycyl]amino)(phenyl)ethanoic acid	-	68570	
3.4.21.98	(2S)-2-[(tert-butoxycarbonyl)amino]-3-(4-hydroxy-3,5-diiodophenyl)propanoic acid	-	53382	
3.4.21.98	(2S)-2-[([(1R,4R)-2-[[(1R)-1-[[(1R)-1-cyclohexyl-2-methoxy-2-oxoethyl]carbamoyl]-2-methylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl]carbonyl)amino]butanoic acid	-	68533	
3.4.21.98	(2S)-2-[[(2-[[(1S)-1-(methoxycarbonyl)-2-methylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl)carbonyl]amino]butanoic acid	-	68479	
3.4.21.98	(2S)-2-[[(2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]-2,2-dimethylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl)carbonyl]amino]butanoic acid	-	68539	
3.4.21.98	(2S)-2-[[(2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-methoxy-2-oxoethyl]carbamoyl]-2,2-dimethylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl)carbonyl]amino]butanoic acid	-	68481	
3.4.21.98	(2S)-2-[[(2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-methoxy-2-oxoethyl]carbamoyl]-2-methylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl)carbonyl]amino]butanoic acid	-	68482	
3.4.21.98	(2S)-[([[3-([[(6S,8S,9R,10S,13S)-13-cyclohexyl-12,15-dioxo-2,7,23-trioxa-11,14-diazatetracyclo[15.3.1.16,9.18,11]tricosa-1(21),17,19-trien-10-yl]carbonyl]amino)-2-oxohexanoyl]amino]acetyl)amino](phenyl)ethanoic acid	-	68571	
3.4.21.98	(2S,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-([7-methoxy-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinazolin-4-yl]oxy)-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide	-	86424	
3.4.21.98	(2S,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-[[2-(3-fluorophenyl)-7-methoxy-8-methylquinazolin-4-yl]oxy]-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide	-	86426	
3.4.21.98	(2S,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-[[2-(4-fluorophenyl)-7-methoxy-8-methylquinazolin-4-yl]oxy]-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide	-	86425	
3.4.21.98	(2S,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-[[2-(4-fluorophenyl)-7-methoxyquinazolin-4-yl]oxy]-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide	-	86164	
3.4.21.98	(2S,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-5-methyl-2-[[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]oxy]-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide	-	86161	
3.4.21.98	(2S,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-5-methyl-4,14-dioxo-2-([2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinazolin-4-yl]oxy)-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide	-	86162	
3.4.21.98	(2S,3aR,11Z,12aS,13aR,15aR)-N-(cyclopropylsulfonyl)-2-[(7-methoxy-8-methyl-2-phenylquinazolin-4-yl)oxy]-4,15-dioxo-1,2,3,3a,4,5,6,7,8,9,10,12a,13,14,15,15a-hexadecahydro-13aH-cyclopenta[c]cyclopropa[g][1,6]diazacyclopentadecine-13a-carboxamide	-	86169	
3.4.21.98	(2S,3aR,11Z,12aS,13aR,15aR)-N-(cyclopropylsulfonyl)-2-[[2-(4-fluorophenyl)-7-methoxy-8-methylquinazolin-4-yl]oxy]-4,15-dioxo-1,2,3,3a,4,5,6,7,8,9,10,12a,13,14,15,15a-hexadecahydro-13aH-cyclopenta[c]cyclopropa[g][1,6]diazacyclopentadecine-13a-carboxamide	-	86170	
3.4.21.98	(2S,4S)-1-((S)-2-((R)-2-cyclohexyl-2-(prop-1-en-2-ylamino)acetamido)-3,3-dimethylbutanoyl)-N-((1S,2R)-1-(cyclopropylsulfonylcarbamoyl)-2-vinylcyclopropyl)-4-phenylpyrrolidine-2-carboxamide	-	40288	
3.4.21.98	(2S,4S)-1-((S)-2-(furan-2-carboxamido)-3,3-dimethylbutanoyl)-N-((S)-4-methyl-1-(4-methylphenylsulfonamido)-1-oxopentan-2-yl)-4-(4-phenyl-1H-1,2,3-triazol-1-yl)pyrrolidine-2-carboxamide	-	235519	
3.4.21.98	(2S,4S)-1-((S)-2-benzamido-2-cyclohexylacetyl)-N-((R)-1-(cyclopropanesulfonamido)-1-oxo-3-phenylpropan-2-yl)-4-(4-phenyl-1H-1,2,3-triazol-1-yl)pyrrolidine-2-carboxamide	-	235520	
3.4.21.98	(2S,4S)-1-((S)-2-benzamido-2-cyclohexylacetyl)-N-((S)-4-methyl-1-(4-methylphenylsulfonamido)-1-oxopentan-2-yl)-4-(4-phenyl-1H-1,2,3-triazol-1-yl)pyrrolidine-2-carboxamide	-	235521	
3.4.21.98	(2S,4S)-1-((S)-2-cyclohexyl-2-(thiophene-2-carboxamido)acetyl)-N-((S)-4-methyl-1-(4-methylphenylsulfonamido)-1-oxopentan-2-yl)-4-(4-phenyl-1H-1,2,3-triazol-1-yl)pyrrolidine-2-carboxamide	-	235522	
3.4.21.98	(2S,4S)-1-((S)-2-cyclohexyl-2-isobutyramidoacetyl)-N-((R)-1-(cyclopropanesulfonamido)-1-oxo-3-phenylpropan-2-yl)-4-(4-phenyl-1H-1,2,3-triazol-1-yl)pyrrolidine-2-carboxamide	-	239746	
3.4.21.98	(2S,4S)-1-((S)-2-isobutyramido-3-phenylpropanoyl)-N-((S)-4-methyl-1-(4-methylphenylsulfonamido)-1-oxopentan-2-yl)-4-(4-phenyl-1H-1,2,3-triazol-1-yl)pyrrolidine-2-carboxamide	-	235523	
3.4.21.98	(2S,5S)-N-(1-[[(2-[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-2-cyclohexyl-3,11,15-trioxo-1,4,10-triazacyclopentadecane-5-carboxamide	-	68483	
3.4.21.98	(2S,5S)-N-(1-[[(2-[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-2-cyclohexyl-3,11,16-trioxo-1,4,10-triazacyclohexadecane-5-carboxamide	-	68484	
3.4.21.98	(2S,5S)-N-(1-[[(2-[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-2-cyclohexyl-3,11,17-trioxo-1,4,10-triazacycloheptadecane-5-carboxamide	-	68485	
3.4.21.98	(2S,5S)-N-(1-[[(2-[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-2-cyclohexyl-3,11,18-trioxo-1,4,10-triazacyclooctadecane-5-carboxamide	-	68486	
3.4.21.98	(2S,6S,12Z,13aS,14aR,16aS)-6-[[(cyclopentyloxy)carbonyl]amino]-2-[4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-yl]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid	-	40238	
3.4.21.98	(3R)-2-[2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl]-N-[1-(cyclobutylmethyl)-3-[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino]-2,3-dioxopropyl]-2-azabicyclo[2.2.1]heptane-3-carboxamide	comparison of binding affinity with human neutrophil elastase, selectivity of 420	59714	
3.4.21.98	(3R)-2-[2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl]-N-[1-(cyclopropylmethyl)-3-[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino]-2,3-dioxopropyl]-2-azabicyclo[2.2.1]heptane-3-carboxamide	comparison of binding affinity with human neutrophil elastase, selectivity of 35	59712	
3.4.21.98	(3R)-2-[[(tert-butylcarbamoyl)amino](cyclohexyl)acetyl]-N-[1-(cyclobutylmethyl)-3-[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino]-2,3-dioxopropyl]-2-azabicyclo[2.2.1]heptane-3-carboxamide	-	59713	
3.4.21.98	(3R)-2-[[(tert-butylcarbamoyl)amino](cyclohexyl)acetyl]-N-[1-(cyclopropylmethyl)-3-[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino]-2,3-dioxopropyl]-2-azabicyclo[2.2.1]heptane-3-carboxamide	-	59711	
3.4.21.98	(3R,12S,16R,17aS)-12-[(tert-butoxycarbonyl)amino]-16-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-1,13-dioxohexadecahydro-1H-pyrrolo[1,2-a][1,4]diazacyclopentadecine-3-carboxylic acid	-	68487	
3.4.21.98	(3S)-3-[(7R,9S,12R)-9-[(1-[[(2-[[2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)carbamoyl]-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-trien-12-yl]cyclohexanecarboxylic acid	-	68488	
3.4.21.98	(3S,12S,16R,17aS)-12-[(tert-butoxycarbonyl)amino]-16-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-1,13-dioxohexadecahydro-1H-pyrrolo[1,2-a][1,4]diazacyclopentadecine-3-carboxylic acid	-	68489	
3.4.21.98	(3S,18S)-18-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-16,19-dioxo-3,4-dihydro-1H-7,2-(epoxyheptanoiminoethano)isoquinoline-3-carboxamide	-	68490	
3.4.21.98	(3S,6S)-6-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-5,8-dioxo-4,7-diazabicyclo[14.3.1]icosa-1(20),16,18-triene-3-carboxamide	-	68492	
3.4.21.98	(4-acetylphenoxy)acetic acid	-	117379	
3.4.21.98	(4-aminophenyl)(2-aminopyridin-3-yl)methanone	-	117382	
3.4.21.98	(4-aminophenyl)(phenyl)methanone	-	117384	
3.4.21.98	(4-methoxyphenyl)(1H-pyrrol-2-yl)methanone	-	117377	
3.4.21.98	(4R)-4-([(2S)-2-acetamido-3-carboxypropanoyl]amino)-5-([(2R,3S)-1-([(2S)-1-[(2S,4R)-4-(benzyloxy)-2-(2-([(1S)-1-(4-bromophenyl)ethyl]carbamoyl)-2-propylhydrazinecarbonyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino)-3-methyl-1-oxopentan-2-yl]amino)-5-oxopentanoic acid	noncovalent binding to enzyme active site, 50% inhibition at 0.000072 mM	254180	
3.4.21.98	(4R)-4-([(2S)-2-acetamido-3-carboxypropanoyl]amino)-5-([(2R,3S)-1-([(2S)-1-[(2S,4R)-4-(benzyloxy)-2-(2-([(1S)-2,3-dihydro-1H-inden-1-yl]carbamoyl)-2-propylhydrazinecarbonyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino)-3-methyl-1-oxopentan-2-yl]amino)-5-oxopentanoic acid	noncovalent binding to enzyme active site, 50% inhibition at 0.0001 mM	254181	
3.4.21.98	(4R)-4-([(2S)-2-acetamido-3-carboxypropanoyl]amino)-5-([(2R,3S)-1-([(2S)-1-[(2S,4R)-4-(benzyloxy)-2-(2-butyl-2-([(1S)-1-phenylethyl]carbamoyl)hydrazinecarbonyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino)-3-methyl-1-oxopentan-2-yl]amino)-5-oxopentanoic acid	noncovalent binding to enzyme active site, 50% inhibition at 0.000099 mM, over 400fold selectivity for enzyme over human leukocyte elastase	254179	
3.4.21.98	(4R)-4-([(2S)-2-acetamido-3-carboxypropanoyl]amino)-5-([(2S,3S)-1-([(2S)-1-[(2S,4R)-4-(benzyloxy)-2-(2-ethyl-2-([(1S)-1-phenylethyl]carbamoyl)hydrazinecarbonyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino)-3-methyl-1-oxopentan-2-yl]amino)-5-oxopentanoic acid	noncovalent binding to enzyme active site, 50% inhibition at 0.000085 mM	254178	
3.4.21.98	(4R)-4-[[(2S)-2-(acetylamino)-3-carboxypropanoyl]amino]-5-[(1-[[(1R)-1-([(2S,4R)-4-(benzyloxy)-2-[(2-[[(1S)-1-phenylethyl]carbamoyl]-2-propylhydrazino)carbonyl]pyrrolidin-1-yl]carbonyl)-2-methylpropyl]carbamoyl]-2-methylbutyl)amino]-5-oxopentanoic acid	noncovalent binding to enzyme active site, 50% inhibition at 0.000078 mM	131746	
3.4.21.98	(4R,6S,7Z,15S,17S)-17-[((7-methoxy-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinolin-4-yl)oxy)methyl]-13-methyl-N-[(1-methylcyclopropyl)sulfonyl]-2,14-dioxo-1,3,13-triazatricyclo[13.2.0.0-4,6-]heptadec-7-ene-4-carboxamide	compound displays high mean clearance of 150 micro per minand mg protein in rat, cynomolgus monkey and human liver microsomes, along with a short half life of less than 10 min	199422	
3.4.21.98	(4R,6S,7Z,15S,17S)-17-[((8-chloro-7-methoxy-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinolin-4-yl)oxy)methyl]-13-methyl-N-[(1-methylcyclopropyl)sulfonyl]-2,14-dioxo-1,3,13-triazatricyclo[13.2.0.0-4,6-]heptadec-7-ene-4-carboxamide	-	199423	
3.4.21.98	(4R,6S,9S,16E)-9-tert-butyl-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-vinylcyclopropyl)-2,8,11-trioxo-3,12-dioxa-1,7,10-triazatetracyclo[16.6.2.14,7.022,26]heptacosa-16,18(26),19,21-tetraene-6-carboxamide	-	81017	
3.4.21.98	(4R,6S,9S,16E)-9-tert-butyl-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-vinylcyclopropyl)-2,8,11-trioxo-3,12-dioxa-1,7,10-triazatetracyclo[20.3.1.14,7.018,23]heptacosa-16,18,20,22-tetraene-6-carboxamide	-	81016	
3.4.21.98	(4S,7S,9R)-4-tert-butyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-2,5-dioxo-10,15-dioxa-3,6-diazatricyclo[14.3.1.16,9]henicosa-1(20),16,18-triene-7-carboxamide	-	68480	
3.4.21.98	(5R,7S,10S)-10-cyclopentyl-N-[(1S)-1-[(cyclopropylamino)(oxo)acetyl]butyl]-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1H,5H-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7(3H)-carboxamide	-	72808	
3.4.21.98	(5R,7S,10S)-10-tert-butyl-3,9,12-trioxo-N-[(1S)-1-[oxo(prop-2-en-1-ylamino)acetyl]butyl]-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1H,5H-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7(3H)-carboxamide	-	72809	
3.4.21.98	(5R,7S,10S)-10-tert-butyl-3,9,12-trioxo-N-[(1S)-1-[oxo[(1-phenylethyl)amino]acetyl]butyl]-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1H,5H-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7(3H)-carboxamide	-	72810	
3.4.21.98	(5R,7S,10S)-10-tert-butyl-3,9,12-trioxo-N-[(1S)-1-[oxo[(pyridin-2-ylmethyl)amino]acetyl]butyl]-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1H,5H-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7(3H)-carboxamide	-	72811	
3.4.21.98	(5R,7S,10S)-10-tert-butyl-N-[(1S)-1-[(cyclobutylamino)(oxo)acetyl]butyl]-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1H,5H-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7(3H)-carboxamide	-	72453	
3.4.21.98	(5R,7S,10S)-10-tert-butyl-N-[(1S)-1-[(cyclopentylamino)(oxo)acetyl]butyl]-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1H,5H-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7(3H)-carboxamide	-	72812	
3.4.21.98	(5R,7S,10S)-10-tert-butyl-N-[(1S)-1-[(cyclopropylamino)(oxo)acetyl]butyl]-3,9,12-trioxo-1,6,7,9,10,11,12,14,15,16,17,18-dodecahydro-5H-2,22:5,8-dimethano-4,13,2,8,11-benzodioxatriazacycloicosine-7(3H)-carboxamide	-	72813	
3.4.21.98	(5R,7S,10S)-10-tert-butyl-N-[(1S)-1-[(cyclopropylamino)(oxo)acetyl]butyl]-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1H,5H-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7(3H)-carboxamide	-	72814	
3.4.21.98	(5R,7S,10S)-10-tert-butyl-N-[(1S)-1-[[(1-methylpropyl)amino](oxo)acetyl]butyl]-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1H,5H-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7(3H)-carboxamide	-	72815	
3.4.21.98	(5R,7S,10S)-N-[(1S)-1-[(benzylamino)(oxo)acetyl]butyl]-10-tert-butyl-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1H,5H-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7(3H)-carboxamide	-	72816	
3.4.21.98	(5R,8S,10R)-5-cyclohexyl-N-(1-[[(2-[[2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-2-methyl-3,6-dioxo-11,15-dioxa-2,4,7-triazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-8-carboxamide	-	68494	
3.4.21.98	(5R,8S,10R)-5-cyclohexyl-N-(1-[[(2-[[2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-3,6-dioxo-11,15-dioxa-2,4,7-triazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-8-carboxamide	-	68495	
3.4.21.98	(5R,8S,10R)-5-tert-butyl-N-(1-[[(2-[[2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-3,6-dioxo-2,11,15-trioxa-4,7-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-8-carboxamide	-	68496	
3.4.21.98	(5S,8S)-N-(1-[[(2-[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-5-cyclohexyl-3,6,14-trioxo-4,7,13-triazabicyclo[14.2.2]icosa-1(18),16,19-triene-8-carboxamide	-	68497	
3.4.21.98	(5S,8S)-N-(1-[[(2-[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-5-cyclohexyl-3,6,14-trioxo-4,7,13-triazabicyclo[14.3.1]icosa-1(20),16,18-triene-8-carboxamide	-	68498	
3.4.21.98	(5S,8S,10R)-5-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-3,6-dioxo-11,16-dioxa-4,7-diazatricyclo[15.3.1.17,10]docosa-1(21),17,19-triene-8-carboxamide	-	68499	
3.4.21.98	(6R,8S,11R)-11-cyclohexyl-N-(1-[[(2-[[2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-10,13-dioxo-2,5-dioxa-9,12-diazatricyclo[14.3.1.16,9]henicosa-1(20),16,18-triene-8-carboxamide	-	68500	
3.4.21.98	(6R,8S,11S)-11-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-10,13-dioxo-2,5-dioxa-9,12-diazatricyclo[13.3.1.16,9]icosa-1(19),15,17-triene-8-carboxamide	-	68501	
3.4.21.98	(6R,8S,11S,18E)-11-tert-butyl-N-((1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-vinylcyclopropyl)-3-methyl-4,10,13-trioxo-5,14-dioxa-3,9,12-triazatricyclo[18.3.1.16,9]pentacosa-1(24),18,20,22-tetraene-8-carboxamide	-	81015	
3.4.21.98	(6S,11S,20S)-11-tert-butyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-10,13-dioxo-2,5-dioxa-9,12-diazatricyclo[13.3.1.16,9]icosa-1(19),15,17-triene-20-carboxamide	-	68581	
3.4.21.98	(6S,8S,9R,10S,13S)-13-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-12,15-dioxo-2,7,23-trioxa-11,14-diazatetracyclo[15.3.1.16,9.18,11]tricosa-1(21),17,19-triene-10-carboxamide	-	68582	
3.4.21.98	(7R,9S)-12-(2,3-dihydro-1H-inden-1-yl)-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-5,5-dimethyl-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide	-	68596	
3.4.21.98	(7R,9S,12R)-12-cyclohexyl-N-(1-[[(2-[[2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide	-	68584	
3.4.21.98	(7R,9S,12R)-12-cyclohexyl-N-(1-[[(2-[[2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-15-methyl-11,14-dioxo-2,6-dioxa-10,13,15-triazatricyclo[15.3.1.17,10]docosa-1(21),17,19-triene-9-carboxamide	-	68573	
3.4.21.98	(7R,9S,12R)-12-cyclohexyl-N-(1-[[(2-[[2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-18-methoxy-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide	-	68586	
3.4.21.98	(7R,9S,12R)-12-cyclohexyl-N-(1-[[(2-[[2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-18-methyl-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide	-	68587	
3.4.21.98	(7R,9S,12R)-12-cyclohexyl-N-(1-[[(2-[[2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-19-methyl-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide	-	68502	
3.4.21.98	(7R,9S,12S)-12-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide	-	68503	
3.4.21.98	(7R,9S,12S)-12-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-11,14-dioxo-2-oxa-6-thia-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide	-	23871	
3.4.21.98	(7R,9S,12S)-12-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-11,14-dioxo-6-(phenylsulfonyl)-2-oxa-6,10,13-triazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide	-	68473	
3.4.21.98	(7R,9S,12S)-12-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-5,5-dimethyl-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide	-	68493	
3.4.21.98	(7R,9S,12S)-12-cyclohexyl-N-(1-[[(2-[[(1S)-2-hydroxy-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide	-	68491	
3.4.21.98	(7R,9S,12S)-12-cyclohexyl-N-[(1S)-1-[[(2-[[(1S)-2-hydroxy-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl]-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide	-	59698	
3.4.21.98	(7R,9S,12S)-12-cyclohexyl-N-[(1S)-1-[[[4-(dimethylamino)-2,4-dioxo-3-phenylbutyl]amino](oxo)acetyl]butyl]-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide	50% inhibition at 400 nM	59697	
3.4.21.98	(7R,9S,12S)-12-tert-butyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-5,5-dimethyl-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide	-	68464	
3.4.21.98	(7R,9S,12S)-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-5,5-dimethyl-12-(1-methylethyl)-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide	-	68465	
3.4.21.98	(7R,9S,12S)-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-5,5-dimethyl-12-(2-methylpropyl)-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide	-	68466	
3.4.21.98	(7R,9S,12S)-N-(1-[[(2-[[(S)-cyano(phenyl)methyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-12-cyclohexyl-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-9-carboxamide	-	68467	
3.4.21.98	(7S,12S,21S)-12-tert-butyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-triene-21-carboxamide	-	68468	
3.4.21.98	(R)-((1R,2S)-1-((2S,4R)-1-((S)-2-(((cyclopentyloxy)carbonyl)amino)-3,3-dimethylbutanoyl)-4-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)pyrrolidine-2-carboxamido)-2-vinylcyclopropyl)(4-methoxybenzyl)phosphinic acid	-	86158	
3.4.21.98	(R)-((1R,2S)-1-((2S,4R)-1-((S)-2-(((cyclopentyloxy)carbonyl)amino)-3,3-dimethylbutanoyl)-4-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)pyrrolidine-2-carboxamido)-2-vinylcyclopropyl)(isopropyl)phosphinic acid	-	86154	
3.4.21.98	(R)-((1S,2S)-1-((2S,4R)-1-((S)-2-(((cyclopentyloxy)carbonyl)amino)-3,3-dimethylbutanoyl)-4-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)pyrrolidine-2-carboxamido)-2-vinylcyclopropyl)(phenyl)phosphinic acid	-	86155	
3.4.21.98	(R)-(4-chlorobenzyl)((1R,2S)-1-((2S,4R)-1-((S)-2-(((cyclopentyloxy)carbonyl)amino)-3,3-dimethylbutanoyl)-4-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)pyrrolidine-2-carboxamido)-2-vinylcyclopropyl)phosphinic acid	-	86157	
3.4.21.98	(R)-benzyl((1R,2S)-1-((2S,4R)-1-((S)-2-(((cyclopentyloxy)carbonyl)amino)-3,3-dimethylbutanoyl)-4-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)pyrrolidine-2-carboxamido)-2-vinylcyclopropyl)phosphinic acid	-	86156	
3.4.21.98	(R)-butyl((1R,2S)-1-((2S,4R)-1-((S)-2-(((cyclopentyloxy)carbonyl)amino)-3,3-dimethylbutanoyl)-4-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)pyrrolidine-2-carboxamido)-2-vinylcyclopropyl)phosphinic acid	-	86153	
3.4.21.98	(S)-((2R,6R,13aS,14S,16aS)-6-(((cyclopentyloxy)carbonyl)amino)-2-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)-5,16-dioxooctadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-14-yl)(2-methoxybenzyl)phosphinic acid	-	167486	
3.4.21.98	(S)-((2R,6R,13aS,14S,16aS,Z)-6-(((cyclopentyloxy)carbonyl)amino)-2-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-14-yl)(2-methoxybenzyl)phosphinic acid	-	86423	
3.4.21.98	(S)-(2-chlorobenzyl)((2R,6R,13aS,14S,16aS)-6-(((cyclopentyloxy)carbonyl)amino)-2-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)-5,16-dioxooctadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-14-yl)phosphinic acid	-	85817	
3.4.21.98	(S)-(2-chlorobenzyl)((2R,6R,13aS,14S,16aS,Z)-6-(((cyclopentyloxy)carbonyl)amino)-2-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-14-yl)phosphinic acid	-	86422	
3.4.21.98	(S)-2-[[(1R,2R,4S)-2-[(R)-1-[((R)-cyclohexylmethoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-butyric acid	21% inhibition at a concentration of 10 micromol	147280	
3.4.21.98	(S)-2-[[(1R,2R,4S)-2-[(R)-1-[((S)-cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-pentanoic acid	35% inhibition at a concentration of 10 micromol	147282	
3.4.21.98	(S)-2-[[(1R,2R,4S)-2-[(S)-1-[((R)-cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-pentanoic acid	37% inhibition at a concentration of 10 micromol	147283	
3.4.21.98	(S)-2-[[(1R,2R,4S)-2-[(S)-1-[((S)-cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-pentanoic acid	-	71630	
3.4.21.98	(S)-2-[[(1R,2R,4S)-2-[(S)-1-[((S)-cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-butyric acid	65% inhibition at a concentration of 10 micromol	147281	
3.4.21.98	(S)-2-[[(1R,2R,4S)-2-[(S)-1-[((S)-cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-pentanoic acid	100% inhibition at a concentration of 10 micromol	71627	
3.4.21.98	(S)-2-[[(1R,2R,4S)-2-[(S)-1-[((S)-cyclohexyl-methylcarbamoyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-pentanoic acid	-	71629	
3.4.21.98	(S)-2-[[(1R,2R,4S)-2-[(S)-1-[((S)-cyclohexyl-methylcarbamoyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-pentanoic acid	-	71628	
3.4.21.98	(S)-2-[[(1R,2R,4S)-2-[(S)-1-[((S)-cyclohexylmethylcarbamoyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-4,4-difluoro-butyric acid	-	71636	
3.4.21.98	(S)-2-[[(1R,4R)-2-[(R)-1-[((S)-cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino]-pentanoic acid	-	71622	
3.4.21.98	(S)-2-[[(1S,4S)-2-[(R)-1-[((S)-cyclohexyl-methoxycarbonylmethyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino]-pentanoic acid	-	71623	
3.4.21.98	(S)-benzyl((2R,6R,13aS,14S,16aS)-6-(((cyclopentyloxy)carbonyl)amino)-2-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)-5,16-dioxooctadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-14-yl)phosphinic acid	-	85816	
3.4.21.98	(S)-benzyl((2R,6R,13aS,14S,16aS,Z)-6-(((cyclopentyloxy)carbonyl)amino)-2-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-14-yl)phosphinic acid	-	86421	
3.4.21.98	(Z)-(1R,4R,6S,14R,16R)-12-tert-butoxycarbonylamino-16-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,13-dioxo-3,12-diaza-tricyclo[12.3.0. 04, 6]heptadec-7-ene-4-carboxylic acid	-	71604	
3.4.21.98	(Z)-(1R,4R,6S,15R,17R)-13-amino-17-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.04,6]octadec-7-ene-4-carboxylic acid	-	71610	
3.4.21.98	(Z)-(1R,4R,6S,15R,17R)-13-tert-butoxycarbonylamino-17-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.04,6]octadec-7-ene-4-carboxylic acid	-	71605	
3.4.21.98	(Z)-(1R,4R,6S,15R,17R)-17-(7-methoxy-2-phenyl-quinolin-4-yloxy)-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.04,6]octadec-7-ene-4-carboxylic acid	-	71609	
3.4.21.98	(Z)-(1R,4R,6S,15R,17S)-17-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,14-dioxo-3,13-diaza-tricyclo-[13.3.0.04,6]octadec-7-ene-4-carboxylic acid	-	71608	
3.4.21.98	(Z)-(1R,4R,6S,16R,18R)-14-amino-18-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,15-dioxo-3,14-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylic acid	-	71611	
3.4.21.98	(Z)-(1R,4R,6S,16R,18R)-14-tert-butoxycarbonylamino-18-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,15-dioxo-3,14-diaza-tricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylic acid	-	71606	
3.4.21.98	(Z)-(1R,4R,6S,17R) and (1S,4R,6S,17S)-13-amino-17-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.04,6]octadeca-7,15-diene-4-carboxylic acid	-	71617	
3.4.21.98	(Z)-(1R,4R,6S,17R,19R)-15-amino-19-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,16-dioxo-3,15-diaza-tricyclo[15.3.0.04,6]icos-7-ene-4-carboxylic acid	-	71612	
3.4.21.98	(Z)-(1R,4R,6S,17R,19R)-15-tert-butoxycarbonylamino-19-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,16-dioxo-3,15-diaza-tricyclo[15.3.0.04,6]icos-7-ene-4-carboxylic acid	-	71607	
3.4.21.98	(Z)-(1R,4R,6S,18R) and (1S,4R,6S,18S)-14-amino-18-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,15-dioxo-3,14-diaza-tricyclo[14.3.0.04,6]nonadeca-7,16-diene-4-carboxylic acid	-	71618	
3.4.21.98	1,1-dimethylethyl [1-cyclohexyl-2-[(1S,5R)-6,6-dichloro-2(S)-[[[1-[1,2-dioxo-2-(2-propenylamino) ethyl]butyl]-amino]carbonyl]-3-azabicyclo[3.1.0]hexan-3-yl]-2-oxoethyl]carbamate	-	25497	
3.4.21.98	1,1-dimethylethyl [2-[(1S,5R)-2(S)-[[[1-(2-amino-1,2-dioxoethyl)butyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hexan-3-yl]-1(S)-cyclohexyl-2-oxoethyl]-carbamate	-	25499	
3.4.21.98	1,1-dimethylethyl[1-cyclohexyl-2-[(1S,5R)-6,6-dichloro-2(S)-[[[1-[2-[[2-[[2-(dimethylamino)-2-oxo-1(S)-phenylethyl]amino]-2-oxoethyl]amino]-1,2-dioxoethyl]-butyl]amino]carbonyl]-3-azabicyclo[3.1.0]hexan-3-yl]-2-oxoethyl]carbamate	-	25496	
3.4.21.98	1,1-dimethylethyl[2-[(1S,5R)-6,6-dichloro-2(S)-[[ [1-(cyclopropyl-methyl)-3-[[2-[[2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl]amino]-2,3-dioxopropyl]-amino]carbonyl]-3-azabicyclo[3.1.0]-hexan-3-yl]-1-cyclohexyl-2-oxoethyl]carbamate	-	71619	
3.4.21.98	1,1-dimethylethyl[2-[(1S,5R)-6,6-dichloro-2(S)-[[1-(cyclobutylmethyl)-3-[[2-[[2-(dimethylamino)-2-oxo-1(S)-phenylethyl]amino]-2-oxomethyl]amino]-2,3-dioxopropylamino]carbonyl]-3-azabicyclo[3.1.0]hexan-3-yl]-1(S)-cyclohexyl-2-oxomethyl]carbamate	-	71620	
3.4.21.98	1,10-phenanthroline	inhibits NS2/3 auto-cleavage and NS3 protease activity	62	
3.4.21.98	1,10-phenanthroline	0.26 mM, 50% inhibition	62	
3.4.21.98	1,2,3,4-tetrahydroacridin-9-amine	inhibitor binding to Zn2+-free enzyme, dissociation constant 0.0017 mM, EC50 value 0.060 mM	199427	
3.4.21.98	1,3,4-tri-O-galloyl-beta-D-glucose	from Saxifraga melanocentra	25492	
3.4.21.98	1,3,6-tri-O-galloyl-beta-D-glucose	from Terminalia chebula	25493	
3.4.21.98	1-(2-(6-Benzyl-3-(3-(tert-butyl)ureido)-2-oxopyrazin-1(2H)-yl)acetamido)-3-hydroxy-N-((4-(trifluoromethyl)phenyl)sulfonyl)cyclobutane-1-carboxamide	-	235792	
3.4.21.98	1-(2-(6-benzyl-3-(3-(tert-butyl)ureido)-5-chloro-2-oxopyrazin-1(2H)-yl)acetamido)-3-(benzyloxy)-N-((4-(trifluoromethyl)phenyl)sulfonyl)cyclobutane-1-carboxamide	-	235793	
3.4.21.98	1-(4-aminophenyl)-2-phenylethane-1,2-dione	-	117381	
3.4.21.98	1-([1-[(1,2-diphenylhydrazino)carbonyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-D-prolyl]amino)-2-ethenylcyclopropanecarboxylic acid	-	36181	
3.4.21.98	1-([1-[2-(2-acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-benzyloxy-pyrrolidine-2-carbonyl]-amino)-2-vinyl-cyclopropanecarboxylic acid	IC50: 0.0097 mM	53434	
3.4.21.98	1-([1-[2-(2-acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-benzyloxy-pyrrolidine-2-carbonyl]-amino)-cyclopropanecarboxylic acid	IC50: 0.33 mM	53433	
3.4.21.98	1-([1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-hydroxy-pyrrolidine-2-carbonyl]-amino)-cyclopropanecarboxylic acid	IC50: above 1 mM	53395	
3.4.21.98	1-([1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-phenoxy-pyrrolidine-2-carbonyl]-amino)-cyclopropanecarboxylic acid	IC50: above 0.08 mM	53396	
3.4.21.98	1-([4-(3'-Acetylamino-biphenyl-3-yloxy)-1-[2-(2-acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-pyrrolidine-2-carbonyl]-amino)-cyclopropanecarboxylic acid	IC50: 0.006 mM	53408	
3.4.21.98	1-4'-hydroxyphenyl-5-phenyl-2(E)-en-1-pentanone	56.5% inhibition	235816	
3.4.21.98	1-aminocyclopropane-1-carboxylic acid ketoacid	electrophilic and acidic compound	18809	
3.4.21.98	1-aminocyclopropane-1-carboxylic acid ketotetrazole	electrophilic and acidic compound	18808	
3.4.21.98	1-aminocyclopropane-1-carboxylic acid pentafluoroethyl ketone	electrophilic and non-acidic compound	18806	
3.4.21.98	1-aminocyclopropanecarboxylic acid	non-electrophilic and acidic compound	18812	
3.4.21.98	1-benzofuran-2-carboxylic acid	-	53376	
3.4.21.98	1-benzothiophene-2-carboxylic acid	-	117351	
3.4.21.98	1-methyl-1H-indole-2-carboxylic acid	-	117352	
3.4.21.98	1-O-(3-O-galloylgalloyl)-2,3,4-tri-O-galloyl-beta-D-glucose	from Saxifraga melanocentra	25494	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(2-bromo-phenoxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.025 mM	53403	
3.4.21.98	1-[[1-[2-(2-acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid	-	117408	
3.4.21.98	1-[[1-[2-(2-acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	-	117407	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(2-thiophen-3-yl-pyridin-3-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: above 0.2 mM	53412	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(3'-nitro-biphenyl-3-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.006 mM	53407	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(3-bromo-phenoxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.05 mM	53402	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(3-morpholin-4-yl-phenoxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.032 mM	53413	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(4'-methoxy-biphenyl-2-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: above 0.2 mM	53410	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(4'-methoxy-biphenyl-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.035 mM	53405	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(4-bromo-phenoxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.025 mM	53399	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(4-bromo-phenylsulfanyl)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.04 mM	53401	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(4-chloro-phenoxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.05 mM	53398	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(4-fluoro-phenoxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.1 mM	53397	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(4-iodo-phenoxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.01 mM	53400	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(5-chloro-quinolin-8-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.1 mM	53419	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(6-methoxy-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.016 mM	53426	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(7-chloro-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.002 mM	53425	
3.4.21.98	1-[[1-[2-(2-acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(7-methoxy-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid	-	117406	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(7-methoxy-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	-	33669	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(7-methoxy-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.0008 mM	33669	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(7-trifluoromethyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.006 mM	53423	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(7-trifluoromethyl-quinolin-4-ylsulfanyl)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.009 mM	53424	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(benzothiazol-2-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.02 mM	53414	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(benzothiazol-2-ylsulfanyl)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.02 mM	53415	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(biphenyl-2-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: above 0.2 mM	53409	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(biphenyl-3-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.006 mM	53406	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(biphenyl-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.035 mM	53404	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(isoquinolin-1-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.008 mM	53420	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(isoquinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.004 mM	53421	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(naphthalen-1-ylmethoxy)-pyrrolidine-2-carbonyl]-amino]-2,2-diethyl-cyclopropanecarboxylic acid	IC50: 0.31 mM	53431	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(naphthalen-1-ylmethoxy)-pyrrolidine-2-carbonyl]-amino]-2-ethyl-cyclopropanecarboxylic acid	IC50: 0.0048 mM	53430	
3.4.21.98	1-[[1-[2-(2-acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(naphthalen-1-ylmethoxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid	IC50: 0.00063 mM	53432	
3.4.21.98	1-[[1-[2-(2-acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(naphthalen-1-ylmethoxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.014 mM	53429	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(pyridin-3-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.19 mM	53417	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(pyridin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.17 mM	53416	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.005 mM	53422	
3.4.21.98	1-[[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-(quinolin-8-yloxy)-pyrrolidine-2-carbonyl]-amino]-cyclopropanecarboxylic acid	IC50: 0.25 mM	53418	
3.4.21.98	12-cyclohexyl-5,5-dimethyl-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo(14.3.1.17,10)henicosa-1(19),16(20),17-triene-9-carboxylic acid ((((1-(dimethylcarbamoylphenylmethyl)carbamoyl)-methyl)aminooxalyl)butyl)amide	50% inhibition at 130 nM	59702	
3.4.21.98	12-tert-butyl-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo(14.3.1.17,10)henicosa-1(19),16(20),17-triene-9-carboxylic acid ((((1-(dimethylcarbamoylphenylmethyl)carbamoyl)methyl)aminooxalyl)butyl)amide	50% inhibition at 700 nM	59699	
3.4.21.98	12-tert-butyl-5,5-dimethyl-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo(14.3.1.17,10)henicosa-1(19),16(20),17-triene-9-carboxylic acid ((((1-(dimethylcarbamoylphenylmethyl)carbamoyl)methyl)-aminooxalyl)butyl)amide	50% inhibition at 200 nM	59703	
3.4.21.98	1H-indole-2-carboxylic acid	-	33666	
3.4.21.98	2'-[1-[2-(2-Acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-5-(1-carboxy-cyclopropylcarbamoyl)-pyrrolidin-3-yloxy]-biphenyl-4-carboxylic acid	IC50: above 0.2 mM	53411	
3.4.21.98	2,2,2-trifluoro-1,1-dimethylethyl[2-[(1S,5R)-2(S)-[[[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]amino]-carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hexan-3-yl]-1(S)-cyclohexyl-2-oxoethyl]carbamate	-	25500	
3.4.21.98	2,2-Dihydroxy-indan-1,3-dione	-	117387	
3.4.21.98	2-(2-(3-(3-(tert-butyl)ureido)-5-chloro-6-(2-cyclohexylethyl)-2-oxopyrazin-1(2H)-yl)acetamido)-4-(pyrimidin-5-yl)-N-((4-(trifluoromethyl)phenyl)sulfonyl)benzamide	-	235977	
3.4.21.98	2-(2-(3-(3-(tert-butyl)ureido)-5-chloro-6-(2-cyclohexylethyl)-2-oxopyrazin-1(2H)-yl)acetamido)-4-fluoro-N-((4-(trifluoromethyl)phenyl)sulfonyl)benzamide	-	235978	
3.4.21.98	2-(2-(3-(3-(tert-butyl)ureido)-5-chloro-6-(2-cyclohexylethyl)-2-oxopyrazin-1(2H)-yl)acetamido)-N-((2-(trifluoromethyl)phenyl)sulfonyl)benzamide	-	235979	
3.4.21.98	2-(2-(3-(3-(tert-butyl)ureido)-5-chloro-6-(2-cyclohexylethyl)-2-oxopyrazin-1(2H)-yl)acetamido)-N-((3-(trifluoromethyl)phenyl)sulfonyl)benzamide	-	235980	
3.4.21.98	2-(2-(3-(3-(tert-butyl)ureido)-5-chloro-6-(2-cyclohexylethyl)-2-oxopyrazin-1(2H)-yl)acetamido)-N-((4-(trifluoromethyl)phenyl)sulfonyl)-4-vinylbenzamide	-	235981	
3.4.21.98	2-(2-(3-(3-(tert-butyl)ureido)-5-chloro-6-(2-cyclohexylethyl)-2-oxopyrazin-1(2H)-yl)acetamido)-Nmethyl-N-((4-(trifluoromethyl)phenyl)sulfonyl)benzamide	-	235982	
3.4.21.98	2-(2-(3-(3-(tert-butyl)ureido)-5-chloro-6-(2-cyclohexylethyl)-2-oxopyrazin-1(2H)-yl)acetamido)-Ntosylbenzamide	-	235983	
3.4.21.98	2-(2-(3-(3-(tert-butyl)ureido)-5-chloro-6-(2-cyclohexylethyl)-2-oxopyrazin-1(2H)-yl)acetamido)benzoic acid	-	235984	
3.4.21.98	2-(2-[2-[2-(4-Carboxy-2-isobutoxycarbonylamino-butyrylamino)-4-methyl-pentanoylamino]-3-mercapto-propionylamino]-ethyl)-benzoic acid	IC50: above 0.1 mM	53357	
3.4.21.98	2-(2-[2-[2-(4-Carboxy-2-isobutoxycarbonylamino-butyrylamino)-4-methyl-pentanoylamino]-3-mercapto-propionylamino]-ethyl)-benzoic acid methyl ester	IC50: 0.054 mM	53354	
3.4.21.98	2-(2-[3-[(tert-butylcarbamoyl)amino]-5-chloro-2-oxo-6-(2-phenylethyl)pyrazin-1(2H)-yl]acetamido)-4-chloro-N-[4-(trifluoromethyl)benzene-1-sulfonyl]benzamide	-	235987	
3.4.21.98	2-(2-[3-[(tert-butylcarbamoyl)amino]-5-chloro-6-(2-cyclohexylethyl)-2-oxopyrazin-1(2H)-yl]acetamido)-N-[4-(trifluoromethyl)benzene-1-sulfonyl]benzamide	lead compound	235988	
3.4.21.98	2-(2-[3-[(tert-butylcarbamoyl)amino]-5-chloro-6-[(naphthalen-1-yl)methyl]-2-oxopyrazin-1(2H)-yl]acetamido)-4-chloro-N-[4-(trifluoromethyl)benzene-1-sulfonyl]benzamide	-	235989	
3.4.21.98	2-(2-[6-benzyl-3-[(tert-butylcarbamoyl)amino]-5-chloro-2-oxopyrazin-1(2H)-yl]acetamido)-N-[4-(trifluoromethyl)benzene-1-sulfonyl]benzamide	-	235990	
3.4.21.98	2-(3-(3-(tert-butyl)ureido)-5-chloro-6-(2-cyclohexylethyl)-2-oxopyrazin-1(2H)-yl)-N-(4-(2-oxo-2-(4-(trifluoromethyl)phenylsulfonamido)ethyl)phenyl)acetamide	-	235993	
3.4.21.98	2-(3-chlorobenzoyl)benzoic acid	-	117363	
3.4.21.98	2-(4-Butyl-phenyl)-2-phenylsulfanyl-indan-1,3-dione	IC50: 0.0017 mM	53387	
3.4.21.98	2-(4-carboxybenzoyl)benzoic acid	-	117361	
3.4.21.98	2-(4-chlorobenzoyl)-6-(methoxycarbonyl)benzoic acid	-	117370	
3.4.21.98	2-(4-chlorobenzoyl)-6-[(dimethylamino)carbonyl]benzoic acid	-	117369	
3.4.21.98	2-(4-chlorobenzoyl)benzoic acid	-	117358	
3.4.21.98	2-(4-chlorobenzyl)benzoic acid	-	117366	
3.4.21.98	2-(4-chlorophenoxy)benzoic acid	-	117364	
3.4.21.98	2-(4-fluorobenzoyl)benzoic acid	-	117359	
3.4.21.98	2-(4-fluorophenoxy)benzoic acid	-	117365	
3.4.21.98	2-(4-hydroxybenzoyl)-4-methylbenzoic acid	-	117373	
3.4.21.98	2-(4-hydroxybenzoyl)benzoic acid	-	117355	
3.4.21.98	2-(4-hydroxybenzyl)benzoic acid	-	117367	
3.4.21.98	2-(4-methoxybenzoyl)benzoic acid	-	117356	
3.4.21.98	2-(4-methylbenzoyl)benzoic acid	-	117357	
3.4.21.98	2-(4-[3-[1-Carboxy-2-(4-hydroxy-3,5-diiodo-phenyl)-ethylcarbamoyloxy]-propoxy]-benzoyl)-benzoic acid	competitive	33668	
3.4.21.98	2-(4-[3-[1-tert-Butoxycarbonyl-2-(4-hydroxy-3,5-diiodo-phenyl)-ethylcarbamoyloxy]-propoxy]-benzoyl)-benzoic acid tert-butyl ester	competitive	33667	
3.4.21.98	2-(6-benzyl-3-(3-(tert-butyl)ureido)-5-chloro-2-oxopyrazin-1(2H)-yl)acetate	-	236022	
3.4.21.98	2-(carboxymethyl)-6-(4-chlorobenzoyl)benzoic acid	-	117368	
3.4.21.98	2-([1-[2-(2-acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-benzyloxy-pyrrolidine-2-carbonyl]-amino)-pentanoic acid	IC50: 0.53 MM	53436	
3.4.21.98	2-([1-[2-(2-acetylamino-2-cyclohexyl-acetylamino)-3-methyl-butyryl]-4-benzyloxy-pyrrolidine-2-carbony]}-amino)-3-mercapto-propionic acid	IC50: 0.14 mM	53435	
3.4.21.98	2-chloro-6-(4-chloro-benzoyl)-benzoic acid	-	117371	
3.4.21.98	2-Hydroxy-2-(1-nitro-ethyl)-indan-1,3-dione	-	117385	
3.4.21.98	2-Hydroxy-2-(2-nitro-cyclopentyl)-indan-1,3-dione	-	117386	
3.4.21.98	2-Methyl-2-phenylsulfanyl-indan-1,3-dione	IC50: 0.0036 mM	53388	
3.4.21.98	2-O-(4-O-galloylgalloyl)-1,3,4-tri-O-galloyl-beta-D-glucose	from Rhodiola kirilowii	25495	
3.4.21.98	2-Phenyl-2-phenylsulfanyl-indan-1,3-dione	IC50: 0.012 mM	53386	
3.4.21.98	2-Phenylsulfanyl-2-p-tolyl-indan-1,3-dione	IC50: 0.0031 mM	53385	
3.4.21.98	2-[1-[1-(1-Carbamoyl-3-methyl-butylcarbamoyl)-2-carboxy-ethylcarbamoyl]-2-cyclohexyl-ethylcarbamoyl]-cyclohexanecarboxylic acid	IC50: 0.015 mM, wild-type enzyme, IC50: 0.017 mM, mutant enzyme K136R, IC50: 0.027 mM, mutant enzyme K136M, IC50: 0.05 mM, mutant enzyme K136S, IC50: above 0.3 mM, mutant enzyme R109Q	53389	
3.4.21.98	2-[1-[2-Carboxy-1-(1-ethylcarbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-cyclohexyl-ethylcarbamoyl]-cyclohexanecarboxylic acid	IC50: 0.032 mM	53390	
3.4.21.98	2-[4-(3-carboxypropyl)benzoyl]benzoic acid	-	117362	
3.4.21.98	2-[4-(trifluoromethyl)benzoyl]benzoic acid	-	117360	
3.4.21.98	2-[[(2,3-dimethylphenoxy)acetyl]amino]-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxamide	an inhibitor identified due to its activity against genotype 4d	236118	
3.4.21.98	3,3'-digalloylprocyanidin B2	-	25491	
3.4.21.98	3,3'-digalloylproprodelphinidin B2	rhodisin	18680	
3.4.21.98	3,4-dichloroisocoumarin	0.03 mM, 50% inhibition	1040	
3.4.21.98	3,6-di-O-galloyl-beta-D-glucose	from Saxifraga melanocentra	12948	
3.4.21.98	3-(2-(3-(3-(tert-b-5-chloro-6-(2-cyclohexylethyl)-2-oxopyrazin-1(2H)-yl)acetamido)-5-(trifluoromethyl)-N-((4-(trifluoromethyl)phenyl)sulfonyl)benzamide	-	236137	
3.4.21.98	3-(2-(3-(3-(tert-butyl)ureido)-5-chloro-6-(2-cyclohexylethyl)-2-oxopyrazin-1(2H)-yl)acetamido)-N-((4-(trifluoromethyl)phenyl)sulfonyl)benzamide	-	236138	
3.4.21.98	3-(2-[2-[2-(4-carboxy-2-isobutoxycarbonylamino-butyrylamino)-4-methyl-pentanoylamino]-3-mercapto-propionylamino]-ethyl)-benzoic acid	IC50: 0.0092 mM	53358	
3.4.21.98	3-(2-[2-[2-(4-Carboxy-2-isobutoxycarbonylamino-butyrylamino)-4-methyl-pentanoylamino]-3-mercapto-propionylamino]-ethyl)-benzoic acid methyl ester	IC50: 0.025 mM	53355	
3.4.21.98	3-(4-acetylphenoxy)propanoic acid	-	117380	
3.4.21.98	3-(4-hydroxy-3,5-diiodophenyl)-2-phenylpropanoic acid	-	53377	
3.4.21.98	3-(4-hydroxy-3,5-diiodophenyl)-3-phenylpropanoic acid	-	53379	
3.4.21.98	3-(4-hydroxy-3,5-diiodophenyl)propanoic acid	-	53378	
3.4.21.98	3-(benzyloxy)-1-(2-(3-(3-(tert-butyl)ureido)-5-chloro-6-(2-cyclohexylethyl)-2-oxopyrazin-1(2H)-yl)acetamido)-N-((4-(trifluoromethyl)phenyl)sulfonyl)cyclobutane-1-carboxamide	-	236146	
3.4.21.98	3-cyclohexyl-2,5-dioxo-12-oxa-1,4-diazatricyclo(11.5.3.016,20)-henicosa-13(21),14,16(20)-triene-18-carboxylic acid ((((1-(dimethylcarbamoylphenylmethyl)carbamoyl)methyl)aminooxalyl)butyl)amide	inhibitor adopts a donutlike conformation and has close contact to A156 methyl group of enzyme	60836	
3.4.21.98	3-[(2R,5S,8S)-8-[(1-[[(2-[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)carbamoyl]-5-cyclohexyl-3,6,14,18-tetraoxo-1,4,7,13-tetraazacyclooctadecan-2-yl]propanoic acid	-	68476	
3.4.21.98	3-[(3S,6R,17S)-17-[(1-[[(2-[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)carbamoyl]-3-cyclohexyl-2,5,8,11-tetraoxo-1,4,7,12-tetraazacycloheptadecan-6-yl]propanoic acid	-	68478	
3.4.21.98	3-[2-(2-Benzyloxycarbonylamino-3-methyl-pentanoylamino)-4-methyl-pentanoylamino]-5,5-difluoro-2-oxo-pentanoic acid	-	53393	
3.4.21.98	3-[2-(2-tert-Butoxycarbonylamino-4-carboxy-butyrylamino)-4-methyl-pentanoylamino]-5,5-difluoro-2-oxo-pentanoic acid	-	53394	
3.4.21.98	3-[2-(2-[2-[2-(2-Acetylamino-3-carboxy-propionylamino)-4-carboxy-butyrylamino]-3,3-diphenyl-propionylamino]-4-carboxy-butyrylamino)-3-cyclohexyl-propionylamino]-5,5-difluoro-2-oxo-pentanoic acid	-	53391	
3.4.21.98	3-[2-(3-tert-butyl-ureido)-2-indan-2-yl-acetyl]-6,6-dichloro-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid(2-carbamoyl-1-cyclobutylmethyl-2-oxo-ethyl)-amide	-	25505	
3.4.21.98	3-[2-(3-tert-butyl-ureido)-3,3-dimethyl-butyryl]-6,6-dichloro-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid(2-carbamoyl-1-cyclobutylmethyl-2-oxo-ethyl)-amide	-	25503	
3.4.21.98	3-[2-[2-(2-Acetylamino-3,3-diphenyl-propionylamino)-4-tert-butoxycarbonyl-butyrylamino]-3-cyclohexyl-propionylamino]-5,5-difluoro-2-oxo-pentanoic acid	-	53392	
3.4.21.98	3beta-O-acetyl-olean-12-en	29.0% inhibition	236192	
3.4.21.98	4-(2-(3-(3-(tert-butyl)ureido)-5-chloro-6-(2-cyclohexylethyl)-2-oxopyrazin-1(2H)-yl)acetamido)-N-((4-(trifluoromethyl)phenyl)sulfonyl)benzamide	-	236217	
3.4.21.98	4-(2-aminoethyl)-benzenesulfonyl fluoride	0.45 mM, 50% inhibition	5252	
3.4.21.98	4-(2-[2-[2-(2-tert-Butoxycarbonylamino-3-methyl-butyrylamino)-4-methyl-pentanoylamino]-4,4-difluoro-but-2-enoylamino]-ethyl)-3-chloro-benzoic acid	highly specific	22459	
3.4.21.98	4-(2-[2-[2-(2-tert-Butoxycarbonylamino-4-carboxy-butyrylamino)-4-methyl-pentanoylamino]-4,4-difluoro-but-2-enoylamino]-ethyl)-3-chloro-benzoic acid	reversible competitive inhibitor, highly specific	22458	
3.4.21.98	4-(2-[2-[2-(4-carboxy-2-isobutoxycarbonylamino-butyrylamino)-4-methyl-pentanoylamino]-3-mercapto-propionylamino]-ethyl)-3-chloro-benzoic acid	IC50: 0.0007 mM	53360	
3.4.21.98	4-(2-[2-[2-(4-Carboxy-2-isobutoxycarbonylamino-butyrylamino)-4-methyl-pentanoylamino]-3-mercapto-propionylamino]-ethyl)-3-chloro-benzoic acid methyl ester	IC50: 0.0032 mM	53361	
3.4.21.98	4-(2-[2-[2-(4-carboxy-2-isobutoxycarbonylamino-butyrylamino)-4-methyl-pentanoylamino]-3-mercapto-propionylamino]-ethyl)-benzoic acid	IC50: 0.002 mM	53359	
3.4.21.98	4-(2-[2-[2-(4-Carboxy-2-isobutoxycarbonylamino-butyrylamino)-4-methyl-pentanoylamino]-3-mercapto-propionylamino]-ethyl)-benzoic acid methyl ester	IC50: 0.017 mM	53356	
3.4.21.98	4-(4-hydroxy-3,5-diiodophenyl)butanoic acid	-	53383	
3.4.21.98	4-(amidinophenyl)-methanesulfonyl fluoride	1.89 mM, 50% inhibition	46006	
3.4.21.98	4-(trifluoroacetyl)benzoic acid	-	117376	
3.4.21.98	4-Benzyloxycarbonylamino-4-[1-(2-mercapto-1-phenethylcarbamoyl-ethylcarbamoyl)-3-methyl-butylcarbamoyl]-butyric acid	IC50: 0.04 mM	53371	
3.4.21.98	4-bromo-2-(2-(3-(3-(tert-butyl)ureido)-5-chloro-6-(2-cyclohexylethyl)-2-oxopyrazin-1(2H)-yl)acetamido)-N-((4-(trifluoromethyl)phenyl)sulfonyl)benzamide	-	236234	
3.4.21.98	4-chloro-1H-indole-2-carboxylic acid	-	117348	
3.4.21.98	4-hydroxy-2-(4-hydroxybenzoyl)benzoic acid	-	117372	
3.4.21.98	4-hydroxy-3,5-diiodobenzoic acid	-	53384	
3.4.21.98	4-Isobutoxycarbonylamino-4-[1-(2-mercapto-1-phenethylcarbamoyl-ethylcarbamoyl)-3-methyl-butylcarbamoyl]-butyric acid	IC50: 0.019 mM	53353	
3.4.21.98	4-methoxy-2-(4-methoxybenzoyl)benzoic acid	-	117375	
3.4.21.98	4-tert-Butoxycarbonylamino-4-(1-[1-[2-(2-chloro-phenyl)-ethylcarbamoyl]-2-mercapto-ethylcarbamoyl]-3-methyl-butylcarbamoyl)-butyric acid	IC50: 0.0065 mM	53374	
3.4.21.98	4-tert-Butoxycarbonylamino-4-(1-[1-[2-(2-chloro-phenyl)-ethylcarbamoyl]-3,3-difluoro-propenylcarbamoyl]-3-methyl-butylcarbamoyl)-butyric acid	-	22457	
3.4.21.98	4-tert-Butoxycarbonylamino-4-[1-(1-carboxy-2-mercapto-ethylcarbamoyl)-3-methyl-butylcarbamoyl]-butyric acid	IC50: above 0.2 mM	53375	
3.4.21.98	4-tert-Butoxycarbonylamino-4-[1-(2-mercapto-1-phenethylcarbamoyl-ethylcarbamoyl)-3-methyl-butylcarbamoyl]-butyric acid	IC50: 0.027 mM	53372	
3.4.21.98	4-[(7R,9S,12R)-9-[(1-[[(2-[[2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)carbamoyl]-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-trien-12-yl]cyclohexanecarboxylic acid	-	37633	
3.4.21.98	4-[1-(1-Benzylcarbamoyl-2-mercapto-ethylcarbamoyl)-3-methyl-butylcarbamoyl]-4-tert-butoxycarbonylamino-butyric acid	IC50: above 0.2 mM	53373	
3.4.21.98	4-[2-[2-(2-Acetylamino-3-carboxy-propionylamino)-4-carboxy-butyrylamino]-3,3-diphenyl-propionylamino]-4-(1-[1-[2-(2-chloro-phenyl)-ethylcarbamoyl]-2-mercapto-ethylcarbamoyl]-2-cyclohexyl-ethylcarbamoyl)-butyric acid	IC50: 2 nM	53369	
3.4.21.98	4-[2-[2-(2-Acetylamino-3-carboxy-propionylamino)-4-carboxy-butyrylamino]-3,3-diphenyl-propionylamino]-4-[1-(1-benzylcarbamoyl-2-mercapto-ethylcarbamoyl)-2-cyclohexyl-ethylcarbamoyl]-butyric acid	IC50: 250 nM	53363	
3.4.21.98	4-[2-[2-(2-Acetylamino-3-carboxy-propionylamino)-4-carboxy-butyrylamino]-3,3-diphenyl-propionylamino]-4-[2-cyclohexyl-1-(2-mercapto-1-phenethylcarbamoyl-ethylcarbamoyl)-ethylcarbamoyl]-butyric acid	IC50: 7 nM	53362	
3.4.21.98	4-[2-[2-(2-Acetylamino-3-carboxy-propionylamino)-4-carboxy-butyrylamino]-3,3-diphenyl-propionylamino]-4-[2-cyclohexyl-1-[1-(2-cyclohexyl-ethylcarbamoyl)-2-mercapto-ethylcarbamoyl]-ethylcarbamoyl]-butyric acid	IC50: 1540 nM	53365	
3.4.21.98	4-[2-[2-(2-Acetylamino-3-carboxy-propionylamino)-4-carboxy-butyrylamino]-3,3-diphenyl-propionylamino]-4-[2-cyclohexyl-1-[1-(indan-2-ylcarbamoyl)-2-mercapto-ethylcarbamoyl]-ethylcarbamoyl]-butyric acid	IC50: 1700 nM	53366	
3.4.21.98	4-[2-[2-(2-Acetylamino-3-carboxy-propionylamino)-4-carboxy-butyrylamino]-3,3-diphenyl-propionylamino]-4-[2-cyclohexyl-1-[2-mercapto-1-(2-phenyl-cyclopropylcarbamoyl)-ethylcarbamoyl]-ethylcarbamoyl]-butyric acid	IC50: 1500 nM	53367	
3.4.21.98	4-[2-[2-(2-Acetylamino-3-carboxy-propionylamino)-4-carboxy-butyrylamino]-3,3-diphenyl-propionylamino]-4-[2-cyclohexyl-1-[2-mercapto-1-(3-phenyl-propylcarbamoyl)-ethylcarbamoyl]-ethylcarbamoyl]-butyric acid	IC50: 210 nM	53364	
3.4.21.98	4-[2-[2-(2-Acetylamino-3-carboxy-propionylamino)-4-carboxy-butyrylamino]-3,3-diphenyl-propionylamino]-4-[2-cyclohexyl-1-[2-mercapto-1-(methyl-phenethyl-carbamoyl)-ethylcarbamoyl]-ethylcarbamoyl]-butyric acid	IC50: 0.07 mM	53368	
3.4.21.98	4MeBu-P-norvaline-(CO)-GMSYS-NH2	CVS4440	86410	
3.4.21.98	5-bromo-1H-indole-2-carboxylic acid	-	117343	
3.4.21.98	5-bromo-2-(4-hydroxybenzoyl)benzoic acid	-	117374	
3.4.21.98	5-chloro-1-benzofuran-2-carboxylic acid	-	117353	
3.4.21.98	5-chloro-1H-indole-2-carboxylic acid	-	117344	
3.4.21.98	5-cyclohexyl-3,6-dioxo-11,16-dioxa-4,7-diazatricyclo(15.3.1.17,10)-docosa-1(21),17,19-triene-8-carboxylic acid ((((1-(dimethylcarbamoylphenylmethyl)carbamoyl)methyl)aminooxalyl)butyl)amide	-	59700	
3.4.21.98	5-fluoro-1H-indole-2-carboxylic acid	-	117342	
3.4.21.98	5-methoxy-1-benzothiophene-2-carboxylic acid	-	117354	
3.4.21.98	5-methoxy-1H-indole-2-carboxylic acid	-	117346	
3.4.21.98	5-methyl-1H-indole-2-carboxylic acid	-	117345	
3.4.21.98	6,6-dichloro-3-[2-cyclohexyl-2-(3-cyclohexyl-ureido)-acetyl]-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid(2-carbamoyl-1-cyclobutylmethyl-2-oxo-ethyl)-amide	-	25501	
3.4.21.98	6-(2-ethoxyphenyl)-3-(2-methylfuran-3-yl)[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole	an inhibitor identified due to its activity against genotype 4d	236320	
3.4.21.98	6-chloro-1H-indole-2-carboxylic acid	-	117347	
3.4.21.98	7-bromo-1H-indole-2-carboxylic acid	-	117350	
3.4.21.98	7-chloro-1H-indole-2-carboxylic acid	-	117349	
3.4.21.98	Ac-Asp-Glu-Leu-Ile-Cha-Cys-OH	-	38304	
3.4.21.98	Ac-DDIVPC-OH	0.04 mM, 50% inhibition	47005	
3.4.21.98	Ac-DVIVPC-OH	0.0075 mM, 50% inhibition	47006	
3.4.21.98	Ac-FASGKR-arginylaldehyde	competitive, 50% inhibition at about 0.001 mM	132485	
3.4.21.98	acetyl-3,3-diphenylalanine-beta-cyclohexylalanine-Cys-OH	0.3 mM, 50% inhibition	47011	
3.4.21.98	acetyl-Asp-(D-Glu)-(allyloxycarbonyl-L-lysine)-(L-cyclohexylalanine)-Cys-OH	-	7554	
3.4.21.98	acetyl-Asp-(D-Glu)-Leu-Ile-L-cyclohexylalanine-Cys-OH	-	7552	
3.4.21.98	acetyl-Asp-(D-Glu)-Tyr-Ile-L-cyclohexylalanine-Cys-OH	-	7553	
3.4.21.98	acetyl-Asp-(D-glutamine)-Leu-Ile-L-cyclohexylalanine-Cys-OH	-	7555	
3.4.21.98	acetyl-Asp-(D-homoglutamate)-Leu-Ile-L-cyclohexylalanine-Cys-OH	-	8513	
3.4.21.98	acetyl-Asp-(D-homoleucine)-Leu-Ile-(L-cyclohexylalanine)-Cys-OH	-	7556	
3.4.21.98	acetyl-Asp-D-(gamma-carboxyglutamic acid)-Leu-Ile-(beta-cyclohexylalanine)-Cys	-	54309	
3.4.21.98	acetyl-Asp-D-Glu-Leu-Ile-(beta-cyclohexylalanine)-Cys-(Me)Ala-Ser-His-Leu-NH2	IC50: 0.0006 mM, inhibitor is cleaved by NS3/4A protease	54303	
3.4.21.98	acetyl-Asp-Glu-(3,3-diphenylalanine)-Glu-(beta-cyclohexylalanine)-Cys	-	54308	
3.4.21.98	acetyl-Asp-Glu-(3,3-diphenylalanine)-Ile-(beta-cyclohexylalanine)-Cys	-	54307	
3.4.21.98	acetyl-Asp-Glu-(3,3-diphenylalanine)-Ile-(beta-cyclohexylalanine)-Cys-(Me)Ala-Ser-His-Leu-NH2	IC50: 0.0034 mM, inhibitor is cleaved by NS3/4A protease	54300	
3.4.21.98	acetyl-Asp-Glu-(diaminopropionyl)-(N-beta-dansyl)-Glu-(beta-cyclohexylalanine)-Cys-OH	-	7551	
3.4.21.98	acetyl-Asp-Glu-3,3-diphenylalanine-Glu-beta-cyclohexylalanine-Cys-OH	0.00005 mM, 50% inhibition	21073	
3.4.21.98	acetyl-Asp-Glu-3,3-diphenylalanine-Ile-beta-cyclohexylalanine-OH	0.046 mM, 50% inhibition	47017	
3.4.21.98	acetyl-Asp-Glu-Leu-Glu-(beta-cyclohexylalanine)-Cys	-	54306	
3.4.21.98	acetyl-Asp-Glu-Leu-Glu-beta-cyclohexylalanine-Cys-OH	0.0026 mM, 50% inhibition	47018	
3.4.21.98	acetyl-Asp-Glu-Leu-Ile-beta-cyclohexylalanine-Cys-OH	0.00006 mM, 50% inhibition	47019	
3.4.21.98	acetyl-Asp-Glu-Met-Glu-beta-cyclohexylalanine-Cys-OH	0.00035 mM, 50% inhibition	47020	
3.4.21.98	acetyl-Asp-Glu-Met-Glu-Glu-Cys	-	54305	
3.4.21.98	acetyl-Asp-Glu-Met-Glu-Glu-Cys-OH	0.001 mM, 50% inhibition	47021	
3.4.21.98	acetyl-Asp-Glu-Val-Val-Pro-boroAlg-OH	the inhibitor binds in an antiparrallel manner to beta-strand E2 and interacts with the unprimed sites of the substrate binding pocket. In the NS3/NS4 inhibitor complex, the inhibitor behaves like a reaction intermediate analog. In the absence of the cofactor, inhibitor binding is an order of magnitude weaker	54310	
3.4.21.98	acetyl-DEMEEC-OH	-	22564	
3.4.21.98	acetyl-DYPSPC-OH	-	22566	
3.4.21.98	acetyl-ECTTPC-OH	-	22565	
3.4.21.98	acetyl-EDVVCC-OH	-	22567	
3.4.21.98	acetyl-EEVVP-norvaline-(CO)-GMSYS-NH2	CVS4437	86408	
3.4.21.98	acetyl-EEVVP-norvaline-(CO)-phenethylamide	CVS4442	86409	
3.4.21.98	acetyl-Glu-3,3-diphenylalanine-Glu-beta-cyclohexyalanine-Cys-OH	0.0014 mM, 50% inhibition	47022	
3.4.21.98	acetyl-Glu-Asp-Val-Val-(alpha-aminobutyryl)-Cys-(1,2,3,4-tetrahydroisoquinoline-3-L-carboxyl)-Nle-Ser-Tyr-NH2	IC50: 0.0019 mM, inhibitor is cleaved by NS3/4A protease	54301	
3.4.21.98	acetyl-Glu-Asp-Val-Val-(alpha-aminobutyryl)-Cys-(Me)Ala-Nle-Ser-Tyr-NH2	IC50: 0.0035 mM, inhibitor is cleaved by NS3/4A protease	54299	
3.4.21.98	acetyl-Glu-Asp-Val-Val-Leu-Cys-(1,2,3,4-tetrahydroisoquinoline-3-L-carboxyl)-Nle-Ser-Tyr-NH2	IC50: 0.001 mM, inhibitor is cleaved by NS3/4A protease	54302	
3.4.21.98	acetyl-Glu-beta-cyclohexylalanine-Cys-OH	0.46 mM, 50% inhibition	47023	
3.4.21.98	acetyl-Glu-Leu-Glu-beta-cyclohexylalanine-Cys-OH	5 mM, 50% inhibition	47789	
3.4.21.98	acetyl-P-norvaline-(CO)-GMSYS-NH2	CVS4441	86414	
3.4.21.98	acetyl-QSVVCC-OH	-	22568	
3.4.21.98	acetyl-VVP-norvaline-(CO)-G-NH2	SCH212986	167816	
3.4.21.98	acetyl-VVP-norvaline-(CO)-S(Bzl)-NH2	SCH215426	167817	
3.4.21.98	alpha1-anitrypsin	-	132484	
3.4.21.98	antibody Fv fragment	specific for the HCV NS3 protease domain, IC50: 71.3 nM	54304	
3.4.21.98	Aprotinin	-	405	
3.4.21.98	Asp-Glu-Leu-Ile-L-cyclohexylalanine-aminobutyryl-(Me)Ala-Ser-His-Leu	IC50: 5 mM	54314	
3.4.21.98	Asp-Glu-Leu-Ile-L-cyclohexylalanine-Cys-OH	IC50: 15 nM	54311	
3.4.21.98	Asp-Glu-Leu-Ile-L-cyclohexylalanine-Cys-Pro-L-cyclohexylalanine-Asp-Leu	IC50 below 0.2 nM	54313	
3.4.21.98	Asp-Glu-Leu-Ile-L-cyclohexylalanine-Cys-Pro-Nle-Ser-Leu	IC50: 10 nM	54312	
3.4.21.98	asunaprevir	-	236356	
3.4.21.98	benzyl 1-([[(2S)-1-[(1R,5S)-2-[(4-amino-1-cyclopropyl-3,4-dioxobutan-2-yl)carbamoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hex-3-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]amino)cyclohexanecarboxylate	-	86416	
3.4.21.98	benzyl((S)-1-cyclohexyl-2-((2S,4S)-2-(((R)-1-(cyclopropanesulfonamido)-1-oxo-3-phenylpropan-2-yl)carbamoyl)-4-(4-phenyl-1H-1,2,3-triazol-1-yl)pyrrolidin-1-yl)-2-oxoethyl)carbamate	-	236360	
3.4.21.98	benzyloxycarbonyl-L-Ile-L-Leu-L-(difluoro)aminobutyric acid	-	117917	
3.4.21.98	BI201335	-	199424	
3.4.21.98	BILN 2061	significantly less active on genotype 2 and 3 enzyme	3743	
3.4.21.98	BILN 2061	-	3743	
3.4.21.98	BILN 2061	potent inhibitor	3743	
3.4.21.98	BILN-2061	used in clinical trials. Potently inhibits Hepatitis C virus replication in human hepatoma cells, but causes cardiac toxicity in experimental animals	6989	
3.4.21.98	BILN-2061	-	6989	
3.4.21.98	BILN-2061	about 90% inhibition at 40 nM	6989	
3.4.21.98	BILN-2061	rapidly reversible NS3 inhibitor	6989	
3.4.21.98	BILN-2061	a NS3 serine protease inhibitor	6989	
3.4.21.98	BILN2061	NS3 protease inhibitor, fully restores MAVS/IPS-1-dependent IFN-alpha promoter activity in Hepatitis C virus-infected cells	71626	
3.4.21.98	BILN2061	-	71626	
3.4.21.98	bis(4-aminophenyl)methanone	-	117383	
3.4.21.98	BMS-605339	-	236362	
3.4.21.98	boceprevir	-	81013	
3.4.21.98	boceprevir	SCH 503034, slowly reversible covalent inhibitor	81013	
3.4.21.98	Bz-Ala-Lys-Arg-Arg-H	-	14452	
3.4.21.98	Bz-Arg-Arg-H	-	25933	
3.4.21.98	Bz-D-Nle-Lys-Arg-Arg-H	-	25942	
3.4.21.98	Bz-Lys-Arg-Arg-H	-	25932	
3.4.21.98	Bz-N-Me-Nle-Lys-Arg-Arg-H	-	25938	
3.4.21.98	Bz-Nle-Ala-Arg-Arg-H	-	14451	
3.4.21.98	Bz-Nle-D-Lys-Arg-Arg-H	-	25941	
3.4.21.98	Bz-Nle-Lys-Ala-Arg-H	-	14450	
3.4.21.98	Bz-Nle-Lys-Arg-(p-Cl)-Phe-H	-	71644	
3.4.21.98	Bz-Nle-Lys-Arg-(p-CN)-Phe-H	-	71640	
3.4.21.98	Bz-Nle-Lys-Arg-(p-guanidinyl)-Phe-H	-	71643	
3.4.21.98	Bz-Nle-Lys-Arg-(p-Ph)-Phe-H	-	71639	
3.4.21.98	Bz-Nle-Lys-Arg-Ala-H	-	14449	
3.4.21.98	Bz-Nle-Lys-Arg-Arg-H	-	10150	
3.4.21.98	Bz-Nle-Lys-Arg-D-Arg-H	-	25939	
3.4.21.98	Bz-Nle-Lys-Arg-His-H	-	71642	
3.4.21.98	Bz-Nle-Lys-Arg-Lys-H	-	14457	
3.4.21.98	Bz-Nle-Lys-Arg-Phe-H	-	14453	
3.4.21.98	Bz-Nle-Lys-Arg-Phg-H	-	25943	
3.4.21.98	Bz-Nle-Lys-Arg-Trp-H	-	25944	
3.4.21.98	Bz-Nle-Lys-Arg-Tyr-H	-	71641	
3.4.21.98	Bz-Nle-Lys-D-Arg-Arg-H	-	25940	
3.4.21.98	Bz-Nle-Lys-Lys(Z)-Arg-H	-	71645	
3.4.21.98	Bz-Nle-Lys-Lys-Arg-B(OH)2	-	25045	
3.4.21.98	Bz-Nle-Lys-Lys-Arg-H	-	14458	
3.4.21.98	Bz-Nle-Lys-N-Me-Arg-Arg-H	-	25936	
3.4.21.98	Bz-Nle-Lys-Phe-Arg-H	-	14454	
3.4.21.98	Bz-Nle-N-Me-Lys-Arg-Arg-H	-	25937	
3.4.21.98	Bz-Nle-Phe-Arg-Arg-H	-	14455	
3.4.21.98	Bz-Nle-Pro-Arg-Arg-H	-	25935	
3.4.21.98	Bz-Phe-Lys-Arg-Arg-H	-	14456	
3.4.21.98	chymostatin	0.71 mM, 50% inhibition	511	
3.4.21.98	Cu2+	-	19	
3.4.21.98	cyclopropanesulfonic acid [(Z)-(1R,4R,6S,15R,17R)-13-amino-17-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.04,6]octadec-7-ene-4-carbonyl]-amide	-	71614	
3.4.21.98	cyclopropanesulfonic acid [(Z)-(1R,4R,6S,15R,17R)-17-(7-methoxy-2-phenyl-quinolin-4-yloxy)-13-methyl-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.04,6]octadec-7-ene-4-carbonyl]-amide	high potency, lacks the P4 substituent	71616	
3.4.21.98	cyclopropanesulfonic acid [(Z)-(1R,4R,6S,15R,17S)-17-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,14-dioxo-3,13-diaza-tricyclo[13.3.0. 04,6]octadec-7-ene-4-carbonyl]-amide	-	71615	
3.4.21.98	cyclopropyl(4-methoxyphenyl)methanone	-	117378	
3.4.21.98	danoprevir	-	201743	
3.4.21.98	danoprevir	approved drug for HCV treatment	201743	
3.4.21.98	daphneolon	63.6% inhibition	236369	
3.4.21.98	daphneticin	69.9% inhibition	236370	
3.4.21.98	daphnetin	79.5% inhibition	8088	
3.4.21.98	daphnoretin	36.5% inhibition	56376	
3.4.21.98	DCSTPC-OH	-	100437	
3.4.21.98	DDIVPC-OH	0.071 mM, 50% inhibition	31441	
3.4.21.98	deca-D-Arg-NH2	-	60825	
3.4.21.98	deldeprevir	-	239748	
3.4.21.98	DEMEEC-NH2	-	100445	
3.4.21.98	DEMEEC-OH	-	100446	
3.4.21.98	dodeca-D-Arg-NH2	-	132483	
3.4.21.98	dodeka-D-Arg-NH2	-	61107	
3.4.21.98	EDTA	inhibits NS2/3 auto-cleavage and NS3 protease activity	21	
3.4.21.98	EDTA	0.007 mM, 50% inhibition	21	
3.4.21.98	EDVVAbuC-OH	-	100506	
3.4.21.98	EGTA	1.6 mM, 50% inhibition	173	
3.4.21.98	embelin	-	209564	
3.4.21.98	faldaprevir	-	236439	
3.4.21.98	fluorescein-L-Asp-D-Glu-L-Leu-L-Ile-L-beta-cyclohexylalanine-L-Cys-L-Pro-L-beta-cyclohexylalanine-L-Asp-L-Leu-NH2	i.e. PepInh-1, noncleavable decapeptidyl inhibitor	60835	
3.4.21.98	glecaprevir	-	236442	
3.4.21.98	grazoprevir	-	236443	
3.4.21.98	GS-9132	an acylthiourea with in vitro activity against Hepatitis C virus genotype 1, inhibits the formation of a functional replication complex. Reversible nephrotoxicity in clinical trials	147277	
3.4.21.98	hepta-D-Arg-NH2	-	60823	
3.4.21.98	hexa-D-Arg-NH2	-	60822	
3.4.21.98	hydrangetin	72.5% inhibition	44236	
3.4.21.98	IDX-320	-	236444	
3.4.21.98	IFN-alpha	-	71603	
3.4.21.98	iodoacetamide	0.26 mM, 50% inhibition	67	
3.4.21.98	ITMN-191	high in vitro potency and specificity	25931	
3.4.21.98	ITMN-191	-	25931	
3.4.21.98	ITMN-191	rapidly reversible inhibitor	25931	
3.4.21.98	ITMN-C	active site inhibitor of the NS3-4A protease	147279	
3.4.21.98	L-aminobutyric acid carboxylic acid	non-electrophilic and acidic compound	18810	
3.4.21.98	L-aminobutyric acid pentafluoroethyl ketone	electrophilic and non-acidic compound	18804	
3.4.21.98	L-norvaline carboxylic acid	non-electrophilic and acidic compound	18811	
3.4.21.98	L-norvaline ketotetrazole	electrophilic and acidic compound	18807	
3.4.21.98	L-norvaline pentafluoroethyl ketone	electrophilic and non-acidic compound	18805	
3.4.21.98	L-Valine, N-[[[(1S)-1-[[(3'aR,6'aS)-1'-(cyclopropylcarbonyl)hexahydro-2'-oxospiro[cyclobutane-1,3'(4'H)-pyrrolo[3,2-b]pyrrol]-4'-yl]carbonyl]-2-methylpropyl]amino]carbonyl]-, 1,1-dimethylethyl ester	-	117401	
3.4.21.98	L-Valine, N-[[[(1S)-1-[[(3'aR,6'aS)-1'-(cyclopropylcarbonyl)hexahydro-2'-oxospiro[cyclobutane-1,3'(4'H)-pyrrolo[3,2-b]pyrrol]-4'-yl]carbonyl]-2-methylpropyl]amino]carbonyl]-, methyl ester	-	117403	
3.4.21.98	L-Valine, N-[[[(1S)-1-[[(3'aR,6'aS)-1'-(cyclopropylcarbonyl)hexahydro-2'-oxospiro[cyclobutane-1,3'(4'H)-pyrrolo[3,2-b]pyrrol]-4'-yl]carbonyl]-2-methylpropyl]amino]carbonyl]-, phenylmethyl ester	-	117402	
3.4.21.98	L-Valine, N-[[[(1S)-1-[[(3'aR,6'aS)-1'-(cyclopropylcarbonyl)hexahydro-2'-oxospiro[cyclobutane-1,3'(4'H)-pyrrolo[3,2-b]pyrrol]-4'-yl]carbonyl]-2-methylpropyl]amino]sulfonyl]-, 1,1-dimethylethyl ester	-	117398	
3.4.21.98	methyl 2-(2-(3-(3-(tert-butyl)ureido)-5-chloro-6-(2-cyclohexylethyl)-2-oxopyrazin-1(2H)-yl)acetamido)benzoate	-	236460	
3.4.21.98	methyl [5-(thiophen-2-ylcarbonyl)-1H-benzimidazol-2-yl]carbamate	inhibitor binding to Zn2+-free enzyme, dissociation constant 0.0019 mM, EC50 value 0.00003 mM	199426	
3.4.21.98	MK-5172	-	239747	
3.4.21.98	MK-7009	i.e. (1R,21S,24S)-21-tert-butyl-N-((1R,2R)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-ethylcyclopropyl)-16,16-dimethyl-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,70.06,11]heptacosa-6,8,10-triene-24-carboxamide, potent and selective inhibitor of hepatitis C virus NS3/4A protease	19232	
3.4.21.98	additional information	alpha-ketoacids incorporating difluoroaminobutyric acid in the p1 position are potent slow binding inhibitors	2	
3.4.21.98	additional information	many NS3 protease inhibitors have taken advantage of an unusual product inhibition by N-terminal products of cleavage at the polyprotein processing sites	2	
3.4.21.98	additional information	solid-phase synthesis of peptidomimetic inhibitors	2	
3.4.21.98	additional information	the effect of prime-site occupancy on the enzyme structure	2	
3.4.21.98	additional information	inhibitors with electrophilic C-terminal residues are generally non-selective while compounds with non-electrophilic C-terminal residues are more selective. Compounds with P1 aminobutyric acid residues are non-selective, while 1-aminocyclopropanecarboxylic acid and norvaline-based inhibitors are generally selective. Most potent and selective inhibitors contain a non-electrophilic phenyl acyl sulfonamide C-terminal residue	2	
3.4.21.98	additional information	the P1 and P2 positions are most important for inhibitor binding, whilst the P3 and P4 positions have much less effect	2	
3.4.21.98	additional information	human leukocyte antigen A2–restricted epitope in which substitutions at 5 of 9 residues destroy the protease	2	
3.4.21.98	additional information	EGTA and zinc metalloprotease inhibitors bestatin, phosphoramidon and thiorphan have no effect on NS2/3 auto-cleavage and NS3 protease activity. No inhibitory effect of the NS4A peptide on NS2/3 auto-cleavage, additionally the NS4A peptide does not significantly affect the sensitivity of NS2/3 autocleavage to zinc chelation, but has a marked effect on NS3 protease activity, rendering this activity approximately 3fold more resistant to zinc chelation	2	
3.4.21.98	additional information	methylated 3,3'-digalloylproprodelphinidin B2, hexanoylated (-)-epigallocatechin-3-O-gallate, (-)-epigallocatechin, (-)-epicatechin, gallic acid, luetolin, tyrosol and salidroside show no activity up to 100 micromol	2	
3.4.21.98	additional information	two galloyl residues at 3 and 4 positions of the glucopyranose ring of the plant inhibitors interact with SER139, GLY137, ALA157, and ASP81 by hydrogen bond interaction and with ALA156 and HIE57 by hydrophobic interaction and are essential for the activities of the inhibitors	2	
3.4.21.98	additional information	compounds with urea cappings are more potent and selective than their carbamate counterparts	2	
3.4.21.98	additional information	protease is susceptible to feedback inhibition by the N-terminal products released from the polyprotein substrate after enzymatic cleavage	2	
3.4.21.98	additional information	14-membered ring system is the most potent.The corresponding 13-, 15-, and 16-membered macrocyclic rings deliver less potent inhibitors. Corresponding P1 acylsulfonamides have superior potencies over the corresponding P1 carboxylic acids. Highly potent protease inhibitors lack the P4 substituent	2	
3.4.21.98	additional information	macrocyclic peptidic inhibitors, are less susceptible to hydrolytic degradation by proteases, have markedly improved oral absorption, and pharmacokinetic properties compared to corresponding acyclic analogs	2	
3.4.21.98	additional information	electrophilic compounds with a pentafluoroethyl ketone group show stronger inhibition at pH 8 than pH 6, the difference is only significant at high ionic strength. Electrophilic compounds with an acidic C-terminal group or a cyclic P1 residue show a lower inhibitory effect at pH 8 than at pH 6, inconsistent with a mechanism-based inhibition. All electrophilic compounds have a strong inhibition at pH 6, when mechanism-based inhibition is unlikely	2	
3.4.21.98	additional information	decrease in the efficiency of expression of NS3/4A protease, as the concentration of Hepatitis C virus-infected cells increases	2	
3.4.21.98	additional information	not inhibited by BMS-858	2	
3.4.21.98	additional information	in the absence of Zn+2, the NS3 protease adopts a partially-folded inactive conformation. Identification of ligands binding to the Zn+2-free NS3 protease, that trap the inactive protein, and block the viral life cycle. Ligands show a new inhibition mechanism simultaneously blocking substrate and cofactor interactions in a non-competitive fashion, appropriate for combination therapy, low impact of known resistance-associated mutations and inhibition of NS4A binding, thus blocking its several effects on NS3 protease	2	
3.4.21.98	additional information	susceptibility/efficiency and resistance, respectively, of virus genotypes and variants with respect to antiviral agents, EC50 values, detailed overview	2	
3.4.21.98	additional information	design and synthesis of a series of novel compounds by incorporating different amino acid residues in P1/P1' and P3/P3' position to develop antiviral agents. All designed compounds show moderate anti-HCV NS3 protease activity, detailed structure-activity relationship (SAR) analysis, overview	2	
3.4.21.98	additional information	discovery and synthesis of pyrazinone-based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease, molecular docking and modeling, overview. The compounds, that are very different to the approved drugs and clinical candidates, have potential in the development of inhibitors less sensitive to drug resistance	2	
3.4.21.98	additional information	design and synthesis of a series of potent NS3 protease inhibitors for the treatment of hepatitis C virus, structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides, overview	2	
3.4.21.98	additional information	screening for NS3/4A protease inhibitors with pan-genotypic antiviral activity, improved coverage of resistance associated substitutions, and a decreased risk of hepatotoxicity. The natural peptide substrates of the HCV NS3/4A protease contain a cysteine or threonine at P1, highlighting the small nature of the S1 pocket. While replacing the P1 vinyl with an ethyl on the 3-methyl pyrrolidine series improveds the predicted clearance, the larger ethyl group results in an approximate 5fold loss in both biochemical and cellular GT3 potency. Significantly improved metabolic stability can be realized by adding a fluoro or difluoro to the P1 ethyl group, but at the expense of further compromised GT3 potency. The P1 difluoromethyl substituent appears to be a viable replacement for the reactive vinyl group wherein GT3 potency is maintained and metabolic stability is improved with compound. Compound synthesis and evaluation, detailed overview	2	
3.4.21.98	additional information	structural analysis, differences in how inhibitors fit within the substrate envelope and interact with the binding site trend with differential drug resistance patterns, hydrogen bond interactions between ligands and side chain atoms in the HCV NS3/4A protease active site, and differential van der Waals interactions on the binding surface of HCV NS3/4A protease, detailed overview. There are many basic residues in the S6 pocket, such as R119, R123, R161, and K165, which make conserved interactions with the conserved acidic D or E residue at the P6 position of the substrate. A drug design strategies focusing on inhibitors with a P1-P3 macrocycle and flexible quinoxiline-related P2 moieties may be an optimal strategy, given high potency can be achieved without compromising the resistance profile. Another drug design strategy is extending inhibitors in the P1' and P4-P6 regions to make increased contacts with conserved residues in the S1' and S4-S6 pockets to increase inhibitor potency while decreasing susceptibility to drug resistance mutations. Q80K is a polymorphism that impacts the activity of most protease inhibitors. Boceprevir, telaprevir, simeprevir, danoprevir, asunaprevir, and faldaprevir are susceptible to mutations at Q80. Drug resistance mutations at residues R155, A156, and D168, are located close to the catalytic triad, impact the most inhibitors. Boceprevir and telaprevir are the oldest inhibitors and are susceptible to drug resistance, with main drug resistance mutations at residues V36, T54, R155, and A156	2	
3.4.21.98	additional information	N-(3-cyano-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophen-2-yl)-2-phenoxyacetamide and N-(3-cyano-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophen-2-yl)-2-(naphthalen-2-yloxy)acetamide are not inhibitory. The inhibitory efficacy of four computer-designed and chemically-synthesized small-molecule compounds is evaluated against in vitro-expressed NS3/4A protease from HCV genotype 4a, the most prevalent genotype in Egypt, using a fluorescence-based enzymatic assay, overview. Molecular modeling. No inhibition by N-(3-cyano-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophen-2-yl)-2-phenoxyacetamide (BE115) and N-(3-cyano-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophen-2-yl)-2-(naphthalen-2-yloxy)acetamide (BR116)	2	
3.4.21.98	additional information	the ethyl acetate extraction of Daphne papyracea exhibits an inhibitory effect towards the HCV NS3/4A protease. Eight compounds are identified from the extract. Molecular docking study of the identified inhibitory compounds against HCV NS3/4A protease using boceprevir as a positive control, docking scores, overview	2	
3.4.21.98	additional information	no inhibition by bestatin, EDTA, Mn2+, Mg2+, Ca2+, K+	2	
3.4.21.98	N-((2-(2-(3-(3-(tert-butyl)ureido)-5-chloro-6-(naphthalen-1-ylmethyl)-2-oxopyrazin-1(2H)-yl)acetamido)phenyl)sulfonyl)-4-(trifluoromethyl)benzamide	-	236551	
3.4.21.98	N-((3-(2-(3-(3-(tert-butyl)ureido)-5-chloro-6-(naphthalen-1-ylmethyl)-2-oxopyrazin-1(2H)-yl)acetamido)phenyl)sulfonyl)-4-(trifluoromethyl)benzamide	-	236552	
3.4.21.98	N-((4-(2-(3-(3-(tert-butyl)ureido)-5-chloro- 6-(naphthalen-1-ylmethyl)-2-oxopyrazin-1(2H)-yl)acetamido)phenyl)sulfonyl)-4-(trifluoromethyl)benzamide	-	236553	
3.4.21.98	N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thien-2-yl)-2-(naphthalen-2-yloxy)acetamide	i.e. BE114	236620	
3.4.21.98	N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thien-2-yl)-2-phenoxyacetamide	i.e. BE113	236621	
3.4.21.98	N-(cyclohexylacetyl)-3-methyl-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide	50% inhibition at 0.000037 mM	131737	
3.4.21.98	N-(cyclohexylcarbamoyl)-3-methyl-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide	50% inhibition at 0.000009 mM	131743	
3.4.21.98	N-(cyclopentylcarbamoyl)-3-methyl-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide	50% inhibition at 0.000005 mM	131744	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-(3-chlorophenyl)-N-[(1R,2S)-1-[(cyclopropanesulfonyl)acetyl]-2-ethenylcyclopropyl]-4-hydroxy-L-prolinamide	-	236676	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-biphenyl-4-yl-N-[(1R,2S)-1-[(cyclopropylsulfonyl)acetyl]-2-ethenylcyclopropyl]-4-hydroxy-L-prolinamide	-	236677	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-biphenyl-4-yl-N-[(1R,2S)-1-[(cyclopropylsulfonyl)acetyl]-2-ethenylcyclopropyl]-4-methoxy-L-prolinamide	-	236678	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[[7-(acetylamino)-2-phenylquinolin-4-yl]oxy]-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-L-prolinamide	50% inhibition at 0.000029 mM	131740	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R)-2-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide	-	236679	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R)-2-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl]-4-[(6-methoxyisoquinolin-1-yl)oxy]-L-prolinamide	-	236680	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-carboxy-2-ethenylcyclopropyl]-4-([2-[2-(dimethylamino)-1,3-thiazol-4-yl]pyridin-4-yl]oxy)-L-prolinamide	-	40222	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide	-	40220	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-[(cyclopropanesulfonyl)acetyl]-2-ethenylcyclopropyl]-4-(3-fluorophenyl)-4-hydroxy-L-prolinamide	-	236681	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-[(cyclopropanesulfonyl)acetyl]-2-ethenylcyclopropyl]-4-(4-fluorophenyl)-4-hydroxy-L-prolinamide	-	236682	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-[(cyclopropanesulfonyl)acetyl]-2-ethenylcyclopropyl]-4-hydroxy-4-(3-methoxyphenyl)-L-prolinamide	-	236683	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-[(cyclopropanesulfonyl)acetyl]-2-ethenylcyclopropyl]-4-hydroxy-4-(3-methylphenyl)-L-prolinamide	-	236684	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-[(cyclopropanesulfonyl)acetyl]-2-ethenylcyclopropyl]-4-hydroxy-4-(4-methoxyphenyl)-L-prolinamide	-	236685	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-[(cyclopropanesulfonyl)acetyl]-2-ethenylcyclopropyl]-4-hydroxy-4-phenyl-L-prolinamide	-	236686	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-[(cyclopropylsulfonyl)acetyl]-2-ethenylcyclopropyl]-4-(2,5-dimethylphenyl)-4-hydroxy-L-prolinamide	-	236687	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-[(cyclopropylsulfonyl)acetyl]-2-ethenylcyclopropyl]-4-(3,5-dimethylphenyl)-4-hydroxy-L-prolinamide	-	236688	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-[(cyclopropylsulfonyl)acetyl]-2-ethenylcyclopropyl]-4-(3-fluoro-4-methylphenyl)-4-hydroxy-L-prolinamide	-	236689	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-[(cyclopropylsulfonyl)acetyl]-2-ethenylcyclopropyl]-4-(4-fluoro-3-methylphenyl)-4-hydroxy-L-prolinamide	-	236690	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-[(cyclopropylsulfonyl)acetyl]-2-ethenylcyclopropyl]-4-(5-fluoro-2-methoxyphenyl)-4-hydroxy-L-prolinamide	-	236691	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-[(cyclopropylsulfonyl)acetyl]-2-ethenylcyclopropyl]-4-hydroxy-4-(2'-methoxybiphenyl-4-yl)-L-prolinamide	-	236692	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-[(cyclopropylsulfonyl)acetyl]-2-ethenylcyclopropyl]-4-hydroxy-4-(4'-methoxybiphenyl-3-yl)-L-prolinamide	-	236693	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-[(cyclopropylsulfonyl)acetyl]-2-ethenylcyclopropyl]-4-hydroxy-4-(4-phenoxyphenyl)-L-prolinamide	-	236694	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-[(cyclopropylsulfonyl)acetyl]-2-ethenylcyclopropyl]-4-hydroxy-4-naphthalen-2-yl-L-prolinamide	-	236695	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-[(cyclopropylsulfonyl)acetyl]-2-ethenylcyclopropyl]-4-hydroxy-4-[2-(morpholin-4-ylmethyl)phenyl]-L-prolinamide	-	236696	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-[(cyclopropylsulfonyl)acetyl]-2-ethenylcyclopropyl]-4-hydroxy-4-[3-(morpholin-4-ylmethyl)phenyl]-L-prolinamide	-	236697	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-[(cyclopropylsulfonyl)acetyl]-2-ethenylcyclopropyl]-4-hydroxy-4-[3-(propan-2-yl)phenyl]-L-prolinamide	-	236698	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-[(cyclopropylsulfonyl)acetyl]-2-ethenylcyclopropyl]-4-hydroxy-4-[3-(propan-2-yloxy)phenyl]-L-prolinamide	-	236699	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-[(cyclopropylsulfonyl)acetyl]-2-ethenylcyclopropyl]-4-hydroxy-4-[4-(1,3-thiazol-2-yl)phenyl]-L-prolinamide	-	236700	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-[(cyclopropylsulfonyl)acetyl]-2-ethenylcyclopropyl]-4-hydroxy-4-[4-(1H-pyrrol-1-yl)phenyl]-L-prolinamide	-	236701	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-[(cyclopropylsulfonyl)acetyl]-2-ethenylcyclopropyl]-4-hydroxy-4-[4-(pyridin-2-yl)phenyl]-L-prolinamide	-	236702	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-[(cyclopropylsulfonyl)acetyl]-2-ethenylcyclopropyl]-4-[3-(dimethylamino)phenyl]-4-hydroxy-L-prolinamide	-	236703	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide	50% inhibition at 0.000029 mM	131739	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4S)-4-(1,3-benzothiazol-2-yl)-N-[(1R,2S)-1-[(cyclopropylsulfonyl)acetyl]-2-ethenylcyclopropyl]-4-hydroxy-L-prolinamide	-	236704	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4S)-4-(4-methoxybenzamido)-L-prolyl-N-(cyclopropanesulfonyl)-L-leucinamide	-	236705	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4S)-4-[(naphthalene-2-carbonyl)amino]-L-prolyl-N-(cyclopropanesulfonyl)-L-leucinamide	-	236706	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4S)-4-[2-(2,3-dimethylanilino)benzamido]-L-prolyl-N-(cyclopropanesulfonyl)-L-leucinamide	-	236707	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4S)-N-[(1R,2S)-1-[(cyclopropylsulfonyl)acetyl]-2-ethenylcyclopropyl]-4-hydroxy-4-prop-2-en-1-yl-L-prolinamide	-	236708	
3.4.21.98	N-(tert-butoxycarbonyl)-3-methyl-L-valyl-N-[(1R,2S)-1-[(cyclopropylsulfonyl)acetyl]-2-ethenylcyclopropyl]-4-oxo-L-prolinamide	-	236709	
3.4.21.98	N-(tert-butoxycarbonyl)-D-valyl-(4S)-N-(1-carboxy-2-ethenylcyclopropyl)-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-D-prolinamide	50% inhibition of processing of substrate SEAP-1 at 0.00026 mM	131726	
3.4.21.98	N-(tert-butylcarbamoyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide	inhibitor derived from peptide DDIVPC applying rigidification of the peptide scaffold to the bioactive conformation	199425	
3.4.21.98	N-(tert-butylcarbamoyl)-3-methyl-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide	50% inhibition at 0.000008 mM	131745	
3.4.21.98	N-([(1R,4R)-2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-methoxy-2-oxoethyl]carbamoyl]-2-methylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl]carbonyl)-L-norvaline	-	68532	
3.4.21.98	N-([(1S,4S)-2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-methoxy-2-oxoethyl]carbamoyl]-2-methylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl]carbonyl)-L-norvaline	-	68509	
3.4.21.98	N-acetyl-L-alpha-aspartyl-L-alpha-glutamyl-b-phenyl-L-phenylalanyl-L-alpha-glutamyl-N-[1-(carboxycarbonyl)-3,3-difluoropropyl]-3-cyclohexyl-L-alaninamide	50% inhibition of processing of substrate SEAP-1 at 0.0067 mM	131727	
3.4.21.98	N-acetyl-L-alpha-aspartyl-L-alpha-glutamyl-beta-phenyl-L-phenylalanyl-L-alpha-glutamyl-3-cyclohexyl-L-alanine	1.17 mM, 50% inhibition	47788	
3.4.21.98	N-acetyl-L-alpha-aspartyl-N-[(1S)-2-[[(1S)-1-([(2S,4R)-2-[[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]carbamoyl]-4-[(2-phenylquinolin-4-yl)oxy]pyrrolidin-1-yl]carbonyl)-2,2-dimethylpropyl]amino]-1-cyclohexyl-2-oxoethyl]-D-alpha-glutamine	-	59692	
3.4.21.98	N-acetyl-L-aspartyl-L-glutamyl-L-isoleucyl-L-valyl-(3R)-3-(benzyloxy)-L-prolyl-N-[(1S)-1-phenylethyl]-L-norleucinamide	-	40228	
3.4.21.98	N-tosyl-Phe chloromethyl ketone	-	16387	
3.4.21.98	N-tosyl-Phe chloromethyl ketone	0.03 mM, 50% inhibition	16387	
3.4.21.98	N-[(1S)-1-cyclohexyl-2-[[(2S)-1-(2-{[1-cyclopropyl-4-(cyclopropylamino)-3,4-dioxobutan-2-yl]carbamoyl]-1',3'-dihydrospiro[cyclobutane-1,2'-inden]-3-yl)-3,3-dimethyl-1-oxobutan-2-yl]amino}-2-oxoethyl]pyrazine-2-carboxamide	compound displays an EC50 of 0.8 microM against hepatitis C virus with no toxicity in Huh7 and Vero cells at concentration up to 10 and 100 microM, respectively. Unfortunately, overall cytotoxicity in cell based systems discourages further development	199419	
3.4.21.98	N-[(2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]-2,2-dimethylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl)carbonyl]-L-norvaline	-	68513	
3.4.21.98	N-[(2S)-2-(acetylamino)-2-cyclohexylacetyl]-3-methyl-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide	50% inhibition at 0.000001 mM	131734	
3.4.21.98	N-[(2S)-2-(acetylamino)-2-cyclohexylacetyl]-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(2-phenylquinolin-4-yl)oxy]-L-prolinamide	50% inhibition at 0.000013 mM, no inhibition of human leukocyte elastase, cathepsin B	131728	
3.4.21.98	N-[(2S)-2-(acetylamino)-2-cyclohexylacetyl]-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(6-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide	50% inhibition at 0.000041 mM	131730	
3.4.21.98	N-[(2S)-2-(acetylamino)-2-cyclohexylacetyl]-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(7,8-dimethoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide	50% inhibition at 0.000013 mM	131733	
3.4.21.98	N-[(2S)-2-(acetylamino)-2-cyclohexylacetyl]-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide	50% inhibition at 0.000002 mM	131731	
3.4.21.98	N-[(2S)-2-(acetylamino)-2-cyclohexylacetyl]-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(8-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide	50% inhibition at 0.000005 mM	131732	
3.4.21.98	N-[(2S)-2-(acetylamino)-2-cyclohexylacetyl]-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[[2-(3-methoxyphenyl)quinolin-4-yl]oxy]-L-prolinamide	50% inhibition at 0.000010 mM	131729	
3.4.21.98	N-[(2S)-2-amino-2-cyclohexylacetyl]-3-methyl-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide	50% inhibition at 0.000018 mM	131735	
3.4.21.98	N-[(2S)-2-cyclohexylpropanoyl]-3-methyl-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide	50% inhibition at 0.000037 mM	131736	
3.4.21.98	N-[(2S)-2-[(N-acetyl-L-alpha-aspartyl-D-alpha-glutamyl)amino]-2-cyclohexylacetyl]-L-valyl-(4S)-4-(naphthalen-2-ylmethoxy)-D-prolyl-D-norvaline	-	59691	
3.4.21.98	N-[(cyclobutyloxy)carbonyl]-3-methyl-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide	50% inhibition at 0.000024 mM	131742	
3.4.21.98	N-[(cyclohexyloxy)carbonyl]-3-methyl-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide	50% inhibition at 0.000030 mM	131738	
3.4.21.98	N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-N-[(1R,2R)-1-[(cyclopropylsulfonyl)carbamoyl]-2-(methylideneamino)cyclopropyl]-4-hydroxy-L-prolinamide	-	40278	
3.4.21.98	N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-N-[(1S,2R)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide	50% inhibition at 0.000014 mM	131741	
3.4.21.98	N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4S)-N-[(1R,2S)-1-carboxy-2-ethenylcyclopropyl]-4-phenyl-L-prolinamide	-	40227	
3.4.21.98	N-[(cyclopentyloxy)carbonyl]-L-leucyl-(4R)-N-[(2S,3R)-2-carboxy-3-ethenylcyclopropyl]-4-([7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy)-L-prolinamide	-	85814	
3.4.21.98	N-[(cyclopentyloxy)carbonyl]-L-leucyl-(4R)-N-[(2S,3S)-2-ethenyl-3-phosphonocyclopropyl]-4-([7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy)-L-prolinamide	-	85815	
3.4.21.98	N-[17-[2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methylquinolin-4-yloxy]-13-methyl-2,14-dioxo-3,13-diazatricyclo [13.3.0.0(4,6)]octadec-7-ene-4-carbonyl](cyclopropyl)sulfonamide	HCV replication in a cellular assay (subgenomic 1b replicon) is inhibited with a half-maximal effective concentration (EC50) of 8 nM. The compound is synergistic with alpha interferon and an NS5B inhibitor in the replicon model and additive with ribavirin. In rats, the compound is extensively distributed to the liver and intestinal tract, and the absolute bioavailability is 44% after a single oral administration. Compound concentrations detected in both plasma and liver at 8 h postdosing are above the EC99 value measured in the replicon	26671	
3.4.21.98	N-[2-(2-[3-[(tert-butylcarbamoyl)amino]-5-chloro-2-oxo-6-(2-phenylethyl)pyrazin-1(2H)-yl]acetamido)-4-chlorobenzene-1-sulfonyl]-4-(trifluoromethyl)benzamide	-	236893	
3.4.21.98	N-{17-[8-chloro-2-(4-isopropylthiazol-2-yl)-7-methoxy-quinolin-4-yloxy]-2,14-dioxo-3,15-diazatricyclo [13.3.0.0]octadec-7-ene-4-carbonyl}-(1-methylcyclo propyl)-(1-methylcyclopropyl)sulfonamide	EC50 = 3.76 nM, non-cytotoxic (CC50 above 0.020 nM), and metabolically stable HCV inhibitor. Compound exhibits advantageous drug metabolism and pharmacokinetic properties in rat and dog, with a high liver exposure after oral administration, but limited heart exposure observed in rat	151598	
3.4.21.98	NaCl	-	42	
3.4.21.98	Nalpha-p-tosyl-Lys chloromethyl ketone	-	21188	
3.4.21.98	Nalpha-p-tosyl-Lys chloromethyl ketone	0.15 mM, 50% inhibition	21188	
3.4.21.98	narlaprevir	-	237041	
3.4.21.98	nona-D-Arg-NH2	reduces infection in primary neurons	60821	
3.4.21.98	octa-D-Arg-NH2	-	60824	
3.4.21.98	paritaprevir	-	237045	
3.4.21.98	paritaprevir	approved drug for HCV treatment	237045	
3.4.21.98	peptidyl-alpha ketoamides	-	117915	
3.4.21.98	phenylmethanesulfonyl fluoride	0.6 mM, 50% inhibition	827	
3.4.21.98	ribavirin	-	1304	
3.4.21.98	RNA aptamer G9-I	noncompetitive inhibition, Arg161 as well Arg130 of the NS3 protease domain are essential for interaction with the G9-I aptamer	117918	
3.4.21.98	RNA aptamer G9-II	-	117919	
3.4.21.98	RNA aptamer G9-III	-	117920	
3.4.21.98	SCH 503034	-	71621	
3.4.21.98	SCH-503034	used in clinical trials. Orally bioavailable, covalent, reversible alpha-keto amide inhibitor. Displays potent and time-dependent inhibition of the NS3-4A protease. Inhibitor dissociation constant in the low nanomolar range. Ability to effectively inhibit Hepatitis C virus RNA synthesis in the human hepatoma cells harboring the hepatitis C virus replicon	14448	
3.4.21.98	SCH-503034	-	14448	
3.4.21.98	SCH217135	-	86411	
3.4.21.98	SCH217142	-	86412	
3.4.21.98	SCH217942	-	86413	
3.4.21.98	SCH6	active site inhibitor of the NS3-4A protease	147278	
3.4.21.98	simeprevir	-	237060	
3.4.21.98	simeprevir	approved drug for HCV treatment	237060	
3.4.21.98	sofosbuvir	approved drug for HCV treatment	237065	
3.4.21.98	sovaprevir	-	237066	
3.4.21.98	Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 1'-(cyclopropylcarbonyl)-4'-[(2S)-2-[[(ethylamino)carbonyl]amino]-3-methyl-1-oxobutyl]hexahydro-, (3'aR,6'aS)-	-	117389	
3.4.21.98	Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 1'-(cyclopropylcarbonyl)-4'-[(2S)-2-[[[(cyclopropylmethyl)amino]carbonyl]amino]-3-methyl-1-oxobutyl]hexahydro-, (3'aR,6'aS)-	-	117393	
3.4.21.98	Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 1'-(cyclopropylcarbonyl)-4'-[(2S)-2-[[[[3-(dimethylamino)propyl]methylamino]carbonyl]amino]-3-methyl-1-oxobutyl]hexahydro-, (3'aR,6'aS)-	IC50: 0.00066 mM	53428	
3.4.21.98	Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 1'-(cyclopropylcarbonyl)hexahydro-4'-[(2S)-2-[[[[(1S)-1-(hydroxymethyl)-2-methylpropyl]amino]carbonyl]amino]-3-methyl-1-oxobutyl]-, (3'aR,6'aS)-	-	117404	
3.4.21.98	Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 1'-(cyclopropylcarbonyl)hexahydro-4'-[(2S)-3-methyl-1-oxo-2-[[(2-propenylamino)carbonyl]amino]butyl]-, (3'aR,6'aS)-	-	117396	
3.4.21.98	Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 1'-(cyclopropylcarbonyl)hexahydro-4'-[(2S)-3-methyl-1-oxo-2-[[(propylamino)carbonyl]amino]butyl]-, (3'aR,6'aS)-	-	117390	
3.4.21.98	Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 1'-(cyclopropylcarbonyl)hexahydro-4'-[(2S)-3-methyl-1-oxo-2-[[[(2,2,2-trifluoroethyl)amino]carbonyl]amino]butyl]-, (3'aR,6'aS)-	-	117397	
3.4.21.98	Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 1'-(cyclopropylcarbonyl)hexahydro-4'-[(2S)-3-methyl-2-[[[(1-methylethyl)amino]carbonyl]amino]-1-oxobutyl]-, (3'aR,6'aS)-	-	117392	
3.4.21.98	Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 1'-(cyclopropylcarbonyl)hexahydro-4'-[(2S)-3-methyl-2-[[[[(1S)-2-methyl-1-[[4-(2-pyrimidinyl)-1-piperazinyl]carbonyl]propyl]amino]carbonyl]amino]-1-oxobutyl]-, (3'aR,6'aS)-	-	117405	
3.4.21.98	Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 4',4'''-[sulfonylbis[imino[(2S)-2-(1-methylethyl)-1-oxo-2,1-ethanediyl]]]bis[1'-(cyclopropylcarbonyl)hexahydro]-, (3'aR,3'''aR,6'aS,6'''aS)-	-	117399	
3.4.21.98	Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 4'-[(2S)-2-amino-3-methyl-1-oxobutyl]-1'-(cyclopropylcarbonyl)hexahydro-, monohydrochloride, (3'aR,6'aS)-	-	117400	
3.4.21.98	Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 4'-[(2S)-2-[(aminocarbonyl)amino]-3-methyl-1-oxobutyl]-1'-(cyclopropylcarbonyl)hexahydro-, (3'aR,6'aS)-	-	117388	
3.4.21.98	Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 4'-[(2S)-2-[[(cyclohexylamino)carbonyl]amino]-3-methyl-1-oxobutyl]-1'-(cyclopropylcarbonyl)hexahydro-, (3'aR,6'aS)-	-	117395	
3.4.21.98	Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 4'-[(2S)-2-[[(cyclopentylamino)carbonyl]amino]-3-methyl-1-oxobutyl]-1'-(cyclopropylcarbonyl)hexahydro-, (3'aR,6'aS)-	-	117394	
3.4.21.98	Spiro[cyclobutane-1,3'(2'H)-pyrrolo[3,2-b]pyrrol]-2'-one, 4'-[(2S)-2-[[(cyclopropylamino)carbonyl]amino]-3-methyl-1-oxobutyl]-1'-(cyclopropylcarbonyl)hexahydro-, (3'aR,6'aS)-	-	117391	
3.4.21.98	STAT-C	-	159984	
3.4.21.98	Suc-L-Asp-D-Glu-L-Leu-L-Ile-L-(cyclohexyl)Ala-1-aminocyclopropane-1-carboxylic acid	comparison with inhibitory effect on human leukocyte elastase, porcine pancreatic elastase, bovine pancreatic chymotrypsin, and cathepsin B	35719	
3.4.21.98	Suc-L-Asp-D-Glu-L-Leu-L-Ile-L-(cyclohexyl)Ala-1-aminocyclopropane-1-carboxylic acid	-	35719	
3.4.21.98	Suc-L-Asp-D-Glu-L-Leu-L-Ile-L-(cyclohexyl)Ala-1-aminocyclopropane-1-carboxylic acid-COOH	comparison with inhibitory effect on human leukocyte elastase, porcine pancreatic elastase, bovine pancreatic chymotrypsin, and cathepsin B	35717	
3.4.21.98	Suc-L-Asp-D-Glu-L-Leu-L-Ile-L-(cyclohexyl)Ala-1-aminocyclopropane-1-carboxylic acid-COOH	-	35717	
3.4.21.98	Suc-L-Asp-D-Glu-L-Leu-L-Ile-L-(cyclohexyl)Ala-1-aminocyclopropane-1-carboxylic acid-NHSO2Ph	comparison with inhibitory effect on human leukocyte elastase, porcine pancreatic elastase, bovine pancreatic chymotrypsin, and cathepsin B	35721	
3.4.21.98	Suc-L-Asp-D-Glu-L-Leu-L-Ile-L-(cyclohexyl)Ala-1-aminocyclopropane-1-carboxylic acid-NHSO2Ph	-	35721	
3.4.21.98	Suc-L-Asp-D-Glu-L-Leu-L-Ile-L-(cyclohexyl)Ala-L-2-aminovaleryl-NHSO2Ph	comparison with inhibitory effect on human leukocyte elastase, porcine pancreatic elastase, bovine pancreatic chymotrypsin, and cathepsin B	35720	
3.4.21.98	Suc-L-Asp-D-Glu-L-Leu-L-Ile-L-(cyclohexyl)Ala-L-2-aminovaleryl-NHSO2Ph	-	35720	
3.4.21.98	Suc-L-Asp-D-Glu-L-Leu-L-Ile-L-(cyclohexyl)Ala-L-aminobutyryl ((S)-2-amino-butanoyl)-C2F5	comparison with inhibitory effect on human leukocyte elastase, porcine pancreatic elastase, bovine pancreatic chymotrypsin, and cathepsin B	35716	
3.4.21.98	Suc-L-Asp-D-Glu-L-Leu-L-Ile-L-(cyclohexyl)Ala-L-aminobutyryl ((S)-2-amino-butanoyl)-C2F5	-	35716	
3.4.21.98	Suc-L-Asp-D-Glu-L-Leu-L-Ile-L-(cyclohexyl)Ala-L-Cys-OH	comparison with inhibitory effect on human leukocyte elastase, porcine pancreatic elastase, bovine pancreatic chymotrypsin, and cathepsin B	35718	
3.4.21.98	Suc-L-Asp-D-Glu-L-Leu-L-Ile-L-(cyclohexyl)Ala-L-Cys-OH	-	35718	
3.4.21.98	telaprevir	-	7758	
3.4.21.98	telaprevir	VX-950	7758	
3.4.21.98	telaprevir	VX-950, slowly reversible covalent inhibitor	7758	
3.4.21.98	tert-butyl (1-cyclohexyl-2-[(3R)-3-[(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]pentyl)carbamoyl]-2-azabicyclo[2.2.1]hept-2-yl]-2-oxoethyl)carbamate	-	59708	
3.4.21.98	tert-butyl (1-[[(3R)-3-([1-(2-cyclobutylethyl)-3-[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino]-2,3-dioxopropyl]carbamoyl)-2-azabicyclo[2.2.1]hept-2-yl]carbonyl]-2,2-dimethylpropyl)carbamate	non-preferred name	59707	
3.4.21.98	tert-butyl (1-[[(3R)-3-([1-(cyclopropylmethyl)-3-[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino]-2,3-dioxopropyl]carbamoyl)-2-azabicyclo[2.2.1]hept-2-yl]carbonyl]-2,2-dimethylpropyl)carbamate	non-preferred name	59706	
3.4.21.98	tert-butyl (1R,2S)-1-[[(2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]-2,2-dimethylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl)carbonyl]amino]-2-ethenylcyclopropanecarboxylate	-	68514	
3.4.21.98	tert-butyl (1R,2S)-1-[[(2-[[(1S)-1-[[(1S)-1-cyclohexyl-2-methoxy-2-oxoethyl]carbamoyl]-2,2-dimethylpropyl]carbamoyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]cyclopent-2-en-1-yl)carbonyl]amino]-2-ethenylcyclopropanecarboxylate	-	68515	
3.4.21.98	tert-butyl (2S)-([N-[3-([[(3S,18S)-18-cyclohexyl-16,19-dioxo-3,4-dihydro-1H-7,2-(epoxyheptanoiminoethano)isoquinolin-3-yl]carbonyl]amino)-2-oxohexanoyl]glycyl]amino)(phenyl)ethanoate	-	68516	
3.4.21.98	tert-butyl (2S)-([N-[3-([[(3S,6S)-6-cyclohexyl-5,8-dioxo-4,7-diazabicyclo[14.3.1]icosa-1(20),16,18-trien-3-yl]carbonyl]amino)-2-oxohexanoyl]glycyl]amino)(phenyl)ethanoate	-	68517	
3.4.21.98	tert-butyl (2S)-([N-[3-([[(7R,9S,12S)-12-cyclohexyl-11,14-dioxo-2,6-dioxa-10,13-diazatricyclo[14.3.1.17,10]henicosa-1(20),16,18-trien-9-yl]carbonyl]amino)-2-oxohexanoyl]glycyl]amino)(phenyl)ethanoate	-	68518	
3.4.21.98	tert-butyl (2S)-[([[3-([[(6S,8S,9R,10S,13S)-13-cyclohexyl-12,15-dioxo-2,7,23-trioxa-11,14-diazatetracyclo[15.3.1.16,9.18,11]tricosa-1(21),17,19-trien-10-yl]carbonyl]amino)-2-oxohexanoyl]amino]acetyl)amino](phenyl)ethanoate	-	68519	
3.4.21.98	tert-butyl [(2R,6S,12Z,14aR,16aS)-14a-[(cyclopropylsulfonyl)carbamoyl]-2-[(6-methoxyisoquinolin-1-yl)oxy]-5,16-dioxo-1,2,3,6,7,8,9,11,13a,14,14a,15,16,16a-tetradecahydro-5H-cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecin-6-yl]carbamate	-	68615	
3.4.21.98	tert-butyl [1-([(3R)-3-[(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]-4-methylpentyl)carbamoyl]-2-azabicyclo[2.2.1]hept-2-yl]carbonyl)-2,2-dimethylpropyl]carbamate	non-preferred name	59705	
3.4.21.98	tert-butyl [1-([(3R)-3-[(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]pentyl)carbamoyl]-2-azabicyclo[2.2.1]hept-2-yl]carbonyl)-2,2-dimethylpropyl]carbamate	-	59704	
3.4.21.98	tert-butyl [1-cyclohexyl-2-[(3R)-3-([1-(cyclopropylmethyl)-3-[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino]-2,3-dioxopropyl]carbamoyl)-2-azabicyclo[2.2.1]hept-2-yl]-2-oxoethyl]carbamate	-	59709	
3.4.21.98	tert-butyl [2-[(3R)-3-([1-(cyclobutylmethyl)-3-[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino]-2,3-dioxopropyl]carbamoyl)-2-azabicyclo[2.2.1]hept-2-yl]-1-cyclohexyl-2-oxoethyl]carbamate	-	59710	
3.4.21.98	tert-butyl((S)-1-((2S,4S)-2-(((R)-1-(cyclopropanesulfonamido)-1-oxo-3-phenylpropan-2-yl)carbamoyl)-4-(4-phenyl-1H-1,2,3-triazol-1-yl)pyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-yl)carbamate	-	237087	
3.4.21.98	tert-butyl((S)-1-((2S,4S)-2-(((R)-1-(cyclopropanesulfonamido)-1-oxo-3-phenylpropan-2-yl)carbamoyl)-4-(4-phenyl-1H-1,2,3-triazol-1-yl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate	-	237088	
3.4.21.98	tert-butyl((S)-1-((2S,4S)-2-(((R)-1-(cyclopropanesulfonamido)-1-oxo-3-phenylpropan-2-yl)carbamoyl)-4-(4-phenyl-1H-1,2,3-triazol-1-yl)pyrrolidin-1-yl)-4-methyl-1-oxopentan-2-yl)carbamate	-	237089	
3.4.21.98	tert-butyl((S)-1-((2S,4S)-2-(((S)-4-methyl-1-(4-methylphenylsulfonamido)-1-oxopentan-2-yl)carbamoyl)-4-(4-phenyl-1H-1,2,3-triazol-1-yl)pyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-yl)carbamate	-	237090	
3.4.21.98	tert-butyl((S)-1-cyclohexyl-2-((2S,4S)-2-(((R)-1-(cyclopropanesulfonamido)-1-oxo-3-phenylpropan-2-yl)carbamoyl)-4-(4-phenyl-1H-1,2,3-triazol-1-yl)pyrrolidin-1-yl)-2-oxoethyl)-carbamate	-	237091	
3.4.21.98	tert-butyl((S)-3,3-dimethyl-1-((2S,4S)-2-(((S)-4-methyl-1-(4-methylphenylsulfonamido)-1-oxopentan-2-yl)carbamoyl)-4-(4-phenyl-1H-1,2,3-triazol-1-yl)pyrrolidin-1-yl)-1-oxobutan-2-yl)carbamate	-	237092	
3.4.21.98	tert-butyl((S)-3-(1H-indol-3-yl)-1-((2S,4S)-2-(((S)-4-methyl-1-(4-methylphenylsulfonamido)-1-oxopentan-2-yl)carbamoyl)-4-(4-phenyl-1H-1,2,3-triazol-1-yl)pyrrolidin-1-yl)-1-oxopropan-2-yl)carbamate	-	237093	
3.4.21.98	tert-butyloxacrybonyl-L-Glu-L-Leu-L-(difluoro)aminobutyric acid	-	117916	
3.4.21.98	TMC 435350	rapidly reversible inhibitor	159985	
3.4.21.98	TMC435	small-molecule reversible noncovalent inhibitor of the NS3/4A serine protease	159983	
3.4.21.98	trans-1,2-cyclohexanediamine-N,N,N',N'-tetraacetic acid	0.007 mM, 50% inhibition	48172	
3.4.21.98	undeca-D-Arg-NH2	-	60826	
3.4.21.98	vaniprevir	MK-7009, i.e. (1R,21S,24S)-21-tert-butyl-N-((1R,2R)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-ethylcyclopropyl)-16,16-dimethyl-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,7.06,11]-heptacosa-6,8,10-triene-24-carboxamide	40404	
3.4.21.98	vaniprevir	-	40404	
3.4.21.98	vedroprevir	-	237107	
3.4.21.98	voxilaprevir	GS-9857	239749	
3.4.21.98	VX-950	equally active on enzyme from all three genotypes	4161	
3.4.21.98	VX-950	-	4161	
3.4.21.98	VX-950	used in clinical trials. Orally biovailable tetrapeptide alpha-ketoamide, binds slowly and reversibly to the protease, with an affinity for the genotype 1 Hepatitis C virus NS4-4A protease in the low nanomolar range and a half life of nearly an hour. Moderately potent inhibitor of Hepatitis C virus replication. Achieves a more than a 10000fold suppression of hepatitis C virus RNA in replicon cells treated for 14 days in the presence of relatively low concentrations of the compound	4161	
3.4.21.98	VX-950	telaprevir	4161	
3.4.21.98	[(2R,5S,8S)-8-[(1-[[(2-[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)carbamoyl]-5-cyclohexyl-3,6,14,18-tetraoxo-1,4,7,13-tetraazacyclooctadecan-2-yl]acetic acid	-	71625	
3.4.21.98	[(2R,6R,12Z,13aS,14S,16aS)-6-[[(cyclopentyloxy)carbonyl]amino]-2-([7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-14-yl]phosphonic acid	-	86420	
3.4.21.98	[(3S,6R,17S)-17-[(1-[[(2-[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)carbamoyl]-3-cyclohexyl-2,5,8,11-tetraoxo-1,4,7,12-tetraazacycloheptadecan-6-yl]acetic acid	-	71624	
3.4.21.98	[(Z)-(1R,4R,6S,15R,17R)-4-cyclopropanesulfonylaminocarbonyl-17-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.04,6]octadec-7-en-13-yl]-carbamic acid tert-butyl ester	-	71613	
3.4.21.98	[1-(6-Ethyl-4-methanesulfonyl-5-oxo-hexahydro-pyrrolo[3,2-b]pyrrole-1-carbonyl)-2-methyl-propyl]-carbamic acid tert-butyl ester	IC50: 0.0005 mM	53427	
3.4.21.98	[1-[1-(2-Mercapto-1-phenethylcarbamoyl-ethylcarbamoyl)-3-methyl-butylcarbamoyl]-2-methyl-propyl]-carbamic acid benzyl ester	IC50: 0.4 mM	53370	
3.4.21.98	[1-[2-(2-carbamoyl-1-cyclobutylmethyl-2-oxo-ethylcarbamoyl)-6,6-dichloro-3-aza-bicyclo[3.1.0]hexane-3-carbonyl]-2,2-dimethyl-propyl]-carbamic acid tert-butyl ester	is the most promising of all the inhibitors. With tert-leucine as P3 residue, extremely potent with single digit nanomolar potency in enzymatic assay. Excellent selectivity against elastase. Bioavailability above 10% in rat, monkey, and dog	25502	
3.4.21.98	[2-[2-(2-carbamoyl-1-cyclobutylmethyl-2-oxo-ethylcarbamoyl)-6,6-dichloro-3-aza-bicyclo[3.1.0]hex-3-yl]-1-indan-2-yl-2-oxo-ethyl]-carbamic acid tert-butyl ester	-	25504